ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[FASLG, PRL, HHEX, CCR2, HGS, CX3CR1, PLK2, TIE1, CXCL10, TEK, PF4]
GO:0060244;negative regulation of cell proliferation involved in contact inhibition;6.0;1.0;0.8231203125901445;9.628524252492122;46.9815665635761;8.390779266560578;0.001572430752218078;0.7522251544931926;[PAK1, DACH1]
GO:1900016;negative regulation of cytokine production involved in inflammatory response;8.0;1.0;0.875;9.628524252492122;227.00494280179373;7.379178354882098;0.007597651144391222;0.7523715242355574;[IL1R2]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[DUSP2, DUSP1, CAV1, DUSP6, PPP2R1A]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, GHR, PROK2, TNFSF11, MAP4K1, MAP2K2, DUSP6, KIT, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, CCL19, DRD4, EGF, CSPG4, PKN1]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[LRRK2, EGF, F2R, ADAM9]
GO:0048246;macrophage chemotaxis;8.0;1.0;0.875;9.628524252492122;95.91852822164125;7.212124270218933;0.0032103068185073717;0.7438283705770736;[CX3CR1, LGALS3, EDNRB, NUP85, CCL5, CCL2, AZU1]
GO:0071498;cellular response to fluid shear stress;4.0;0.7980440201809971;0.6490220100904985;9.271849308553389;39.92524609926753;6.8867018697843045;0.0013362620565537933;0.6021862538851576;[MEF2C, PTGS2]
GO:0048245;eosinophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;6.7325511899570465;0.004360933283440787;0.740543606130341;[LGALS3, CCL13, CCL23, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:0030948;negative regulation of vascular endothelial growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;297.5747140953686;7.474488534686424;0.00995955788091634;0.7331650565203278;[HHEX, HGS]
GO:0031915;positive regulation of synaptic plasticity;8.0;0.8653626801206646;0.8076813400603323;9.446202695698167;41.65758488823441;7.57984905034425;0.0013942418768168238;0.7626338329336335;[PTGS2]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, POLA2, BCL6, IFNG, AKT1, RAN]
GO:0046061;dATP catabolic process;12.0;1.0;0.9481203125901445;9.628524252492122;7925.687620454256;8.67846133901236;0.26526563200083675;0.8919372290569614;[SAMHD1]
GO:0016998;cell wall macromolecule catabolic process;6.0;0.7436939687323844;0.6949672969563367;9.040737587590003;64.62185674054949;7.138016298065211;0.0021628353892109253;0.6881587980249038;[LYZ]
GO:0035397;helper T cell enhancement of adaptive immune response;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;141.16491257062583;9.777073627680469;0.004724662583565679;0.875;[CD4]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[DOCK5, NRP1, OLFM4, DNM2, FLNA]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[AKT1, SFN, BARD1, LYN, PLK2, CDKN1A, CHAF1B, CHAF1A, UNG, GTF2H1, PYCARD, RUVBL1, MACROD2, MSH6, MSH2, BLM, FOXO1, BCL6, CNOT3, MCM7, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, TNFRSF1B, RBBP8, E2F7, RAD51, CCNH, CHEK1, ESCO2, POLA1, BRCA2, RAD51C, SGK1, PCNA, RAD54B, RPA1, MLH1, RPA3, DCLRE1A, HMGA1, TOPBP1, POLD3, POLD1, POLE2]
GO:0048012;hepatocyte growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.292166977892469;0.0010376185600805164;0.747921758369865;[NRP1, PAK1, STMN1]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[CCL20, LRRK2, FCER2, CCL2, TLR4, TLR2]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[SPINT2, AKT1, PDGFRB, MEF2C, RUNX2, SPINT1, TGFB1, EGR3, CAV1, NR4A1, NOX4, NRP1, MCM7, TMEM100, ANXA1, ARG1, TNFRSF1B, XCL1, CX3CR1, DTYMK, CCL5, CCL2]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[AP2M1, MMP9, EPHA3, SDC2, PAK1, LYN, PTK2]
GO:2000484;positive regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.069023426578259;0.02521906460756386;0.7767511986393403;[F2R, TLR1, CD2, PYCARD, FFAR2, CD58, TLR2]
GO:0015677;copper ion import;9.0;0.8933024483968273;0.8428918493787028;9.427853557029971;21.372061049954535;7.697632086000634;7.153036497357847E-4;0.7898978880348613;[STEAP4]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[BRCA2, HHEX, SLITRK6, RMI1]
GO:1902692;regulation of neuroblast proliferation;7.0;0.8436909121759173;0.7727648213451592;9.434368238051164;96.82302238471779;6.518977089658987;0.0032405794241536453;0.6843001567857983;[CX3CR1, TGFB1, SMARCD3, LRRK2]
GO:0035023;regulation of Rho protein signal transduction;9.0;0.8436909121759173;0.8180860812682478;9.318369324188282;48.758993290020136;4.879233827729558;0.0016319196251719597;0.645764870037956;[NRP1, ARHGEF10L, STMN1, PDGFRB, PLEKHG1, F2R, ARAP3, FGD4, EPS8L1, ABCA1, BCL6, GPR18, F2RL3]
GO:0035024;negative regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;340.00127024396755;6.832634648514029;0.011379536533788362;0.7646622655359331;[BCL6, STMN1, ARAP3]
GO:0033089;positive regulation of T cell differentiation in thymus;10.0;0.8933024483968273;0.861892236059334;9.577230958104572;998.0942985465404;7.292166977892469;0.03340531794580182;0.7881627702307852;[EGR3, VNN1]
GO:1904754;positive regulation of vascular associated smooth muscle cell migration;9.0;1.0;0.896240625180289;9.628524252492122;244.58802208207217;7.212124270218933;0.008186140984158152;0.7650689957573628;[DOCK5, PAK1]
GO:1902219;negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;756.2955759145742;8.16763571524637;0.025312532304032187;0.8329342821725234;[PTGS2]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[ICAM2, PAK1, KLRK1, MUC15, LYN, CARD9, CLEC4D]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, F13A1, LAMP2, CD36, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, STXBP2, FLNA, LYN, TGFB1, EGF, LHFPL2, PPBP, CD9, PF4]
GO:0006813;potassium ion transport;7.0;0.7980440201809971;0.7499413753476991;9.310070521373587;34.16983994150393;4.61801832846594;0.001143633791982704;0.587085037334763;[KCNK5, KCNG2, KCNH1, KCND2, ATP1B2, ATP1B1, KCNQ1, SLC24A4, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNN3, SLC12A1, KCNJ15, KCNJ16]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, FGF5, TNFSF11, PDGFRB, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, CCR5, SPTAN1, MAP4K1, DUSP6, KIT, HBEGF, CCL5, CCL2, NCAM1, EGF, IL2RB, TEK]
GO:0046085;adenosine metabolic process;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;443.46863639021404;7.474488534686424;0.01484249616411921;0.7784863164434164;[NT5E, ACPP, PTGDR]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PID1, PTGER2, PTAFR, P2RY6, AKT1, FFAR2, PTGDR, DGAT2]
GO:0036109;alpha-linolenic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;214.3732045654151;7.212124270218933;0.0071748782334459795;0.7650689957573628;[ACSL1]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, AKT1, CD36, CD177, PDGFRB, DNM2, IFNG, AGTR1, TLR4, FPR2, PTGS2, GNAI2, KLRK1, TGFB1, NOX4, PTX3]
GO:1904887;Wnt signalosome assembly;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;9.777073627680469;0.0013529121422039536;0.7902410118609202;[LRRK2]
GO:0005983;starch catabolic process;8.0;1.0;0.875;9.628524252492122;666.9679342199055;9.777073627680469;0.02232281652616981;0.875;[MGAM]
GO:0002224;toll-like receptor signaling pathway;11.0;0.6763753087927167;0.7706166067260205;9.040737587590003;409.6592600291497;5.311165509025885;0.01371092676377766;0.7040422034557006;[ITGAM, CTSS, CD36, HAVCR2, CD180, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, S100A8, TLR2, COLEC12, UNC93B1, LY96]
GO:0002467;germinal center formation;5.0;1.0;0.7902410118609202;9.628524252492122;29.459500770284833;7.697632086000634;9.859829789520339E-4;0.6838982747154925;[MEF2C, BCL6, CXCL13]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CHEK1, AKT1, TLR8, TLR7, TLR5, TLR4, ENG, PTGS2, TGFB1, TNFSF14, TNFRSF10B, LTBR]
GO:0006948;induction by virus of host cell-cell fusion;8.0;1.0;0.875;9.628524252492122;77.37443216443229;9.777073627680469;0.0025896526120755235;0.875;[CD4]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[NRP1, HMGB2, FASLG, LGALS3, AKT1, CX3CR1, TNFRSF10B, PF4]
GO:0097756;negative regulation of blood vessel diameter;7.0;0.7436939687323844;0.7227663496233927;9.0689084645567;39.67967046252893;6.113511981550823;0.0013280428609958766;0.663564652301091;[CAV1, PTGS2, SLC8A1, EDNRB, P2RX1]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PYCARD, PPP2R1A, TNFSF12, CAV1, G0S2, INHBA, PPP1CA, MAL, LTBR, ATF3, ITM2C]
GO:0038112;interleukin-8-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CXCR1, CXCR2]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[, NUP107, AKT1, NUP85, NUP88, MMP12, CSE1L, LAMP2, AP2M1, RAB32, SLC27A2, EVI5, BCL6, NLGN1, UNC93B1, EGR2, POLA2, CD24, XPO1, TMED6, STX11, RANBP1, NUPL2, RAMP1, SCARB2, TSC2, ATP1B1, HGS, TGFB1, NUP155, NUP62, NUP133, TBC1D9, IFNG, NUP54, NUP35, RAN]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[, CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, LYN, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, ANXA5, F5, SERPINB10, PTAFR, ALOX5, FLNA, GSN, LRG1, SLCO4C1, SIGLEC5, PF4, HP, F13A1, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, LIN7A, GPR84, CORO1A, ATP8B4, DEFA4, DEFA1, LCN2, LAT, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, CCL8, CCL5, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, ACTN1, SLC11A1, ACTN4, CHIT1, SLPI, CRISPLD2, TLN1, STXBP2, MGST1, CCR1, PRG2, NBEAL2, PPBP, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, LAT2, CEACAM1, CEACAM6, KIT, TLR2, LILRA3, STX11, PAK1, CXCR1, CXCR2, CD58, LHFPL2, LILRB2, LILRB3, QPCT, CD68, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, TGFB1, SYT2, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, SYNGR3, MMP9, CHI3L1, LTF, CLEC12A, RETN, EGF, CD9, S100P, PTX3]
GO:0006401;RNA catabolic process;7.0;0.5945822691631375;0.6482104998387692;8.775746926340293;532.6118641417924;4.304802954008995;0.01782603977326812;0.5710671885190304;[PPP2R1A, MAGOH, RNASE6, RNASE3, RNASE2, LSM5, LSM3, CNOT3, MLH1]
GO:0050873;brown fat cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;6.444869117505266;7.282666309192915E-4;0.6198319182472036;[LAMB3, ADRB2, PTGS2, LRG1]
GO:0070365;hepatocyte differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;24.20171999872632;7.212124270218933;8.100097882234571E-4;0.659069382437994;[HHEX, ANXA1, E2F7]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[PYCARD, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, AZU1, DEFA1, CXCL10, IFNA5, IFNA4, IFNA7, CXCL9, IFNA2, IFNA8, IFNG, TLR8, TLR7, UNC93B1, SAMHD1, CARD9, LILRB1]
GO:0051968;positive regulation of synaptic transmission, glutamatergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.83014596643335;6.375876246018314;0.004546112746301595;0.701062607729944;[NLGN1, TNR, PTGS2, KMO]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[SLC8A1, AKT1, KCND2, PTGS2]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, TNFSF11, CCR6, CCR5, CCR2, AVPR1A, ATP1B1, LAT2, BTK, AGTR1, CX3CR1, CXCR5, CXCR4, FPR2, CXCR6, CXCR1, CXCR2, CCR10, CCR1, CCL20, AZU1, SELE, LAT]
GO:0016575;histone deacetylation;9.0;0.7866048967936545;0.7895430735771163;9.396722638434797;357.60632662761185;5.682729065458369;0.011968761927426838;0.6868556538617572;[ARID4A, NACC2]
GO:0051966;regulation of synaptic transmission, glutamatergic;7.0;0.811012628672052;0.7564256795932265;9.405380701177911;30.61939422688933;5.528578385631111;0.001024803569108247;0.6336511210035629;[MEF2C, NLGN1, LRRK2, PTGS2, KMO, GRM5, CNR1, TNR]
GO:0051603;proteolysis involved in cellular protein catabolic process;6.0;0.6519675769143192;0.6491041010473041;8.270400768338927;49.64990487012002;3.4509241545253704;0.001661737633989536;0.49960073433695684;[, WFS1, HM13, RNF24, SKP2, CTSS, RANBP1]
GO:0060431;primary lung bud formation;8.0;1.0;0.875;9.628524252492122;121.16230854056519;9.083926447120524;0.0040551934278544415;0.839552420951524;[HHEX]
GO:2000172;regulation of branching morphogenesis of a nerve;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.274657408465146;8.390779266560578;0.0019838694397330287;0.7522251544931926;[LRRK2]
GO:0006772;thiamine metabolic process;6.0;0.8653626801206646;0.7558016526504768;9.523163736834295;172.32164456529355;8.390779266560578;0.005767450364188875;0.7522251544931926;[ACPP]
GO:0002052;positive regulation of neuroblast proliferation;8.0;1.0;0.875;9.628524252492122;500.99868276789744;6.781341354126479;0.016767975042699966;0.7217981122146513;[CX3CR1, SMARCD3]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[TFRC, SLC11A1, FPR2, IGHA1, ELANE, MSR1, MARCO, DENND1B, ASGR1, ASGR2, CD36, ANXA1, ANXA3, CEACAM1, RHOU, CD302, IGKC, CXCR1, CXCR2, SORT1, LILRB1, SIGLEC1, RAMP1, SCARB2, NCF4, HP, CXCL16, PYCARD, AP2M1, CD93, TSC2, PRTN3, CALCRL, PLD4, ADRB2, CORO1A, IGLV1-44, CD163, SYT2, CAV1, LRP1B, MARCH3, IGKV3-20, LRP12, LRRK2, GHR, DNM2, PECAM1, COLEC12, NLGN1, LRP1, CEBPE, DLL1, FCGR1B, ATP9A, NLGN4Y, CD6, CD9, FCGR2B]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[TGFA, F5]
GO:0030855;epithelial cell differentiation;4.0;0.5489353771682173;0.5244676885841086;6.961296045910167;21.066225782797595;4.034070439870987;7.050676185779127E-4;0.45630254989846264;[EHF, LGALS3, BASP1, AKT1, MEF2C, ADAM9, ST14, TGFB1, JAG1, CD24, SLC7A11, TMEM100, HHEX, ANXA1, PCNA, E2F7, USH2A]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, NRBP1, TGFA, SPTAN1, TMED6, F5]
GO:0070232;regulation of T cell apoptotic process;9.0;0.7192862368539868;0.7558837436072825;8.8813098506619;22.875998380894767;6.193554689224359;7.656390787466303E-4;0.7129793000169707;[CD274, BLM, SLC46A2, LGALS3, CCL5]
GO:2001259;positive regulation of cation channel activity;9.0;0.7043150770688792;0.7483981637147287;9.126432308694886;526.0857391442704;5.75172193694532;0.017607616242732247;0.6903839525180965;[KCNE3, ADRB2, CTSS]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPG, SIRPB1, PYCARD, STAP1, CCL2, CD36, SLC11A1, AZU1, DNM2, PTX3, FCGR2B]
GO:0098706;ferric iron import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;329.4898826815344;7.9853141584524145;0.011027729851708358;0.8407982897480031;[STEAP4]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[AKT1, BARD1, MARCH3, MARCH1, NLRC4, RNF24, SKP2, NAIP, PCNA, KLHL14, UBE2M, HIST1H2BK]
GO:2001274;negative regulation of glucose import in response to insulin stimulus;9.0;1.0;0.896240625180289;9.628524252492122;211.08179742828042;8.390779266560578;0.007064717798640191;0.8253454670833372;[PID1]
GO:2001275;positive regulation of glucose import in response to insulin stimulus;9.0;1.0;0.896240625180289;9.628524252492122;210.7203529833852;6.832634648514029;0.00705262057834843;0.7456618788553018;[PAK1]
GO:1903980;positive regulation of microglial cell activation;8.0;1.0;0.875;9.628524252492122;155.50143499853152;7.697632086000634;0.005204493087195169;0.7686572628545723;[ITGAM, LRRK2, STAP1]
GO:0046039;GTP metabolic process;10.0;0.8933024483968273;0.861892236059334;9.574457031221845;1313.8843925894662;6.311337724880743;0.043974528200785255;0.7380031166185408;[LRRK2, RAN]
GO:0046037;GMP metabolic process;10.0;0.8259837884571596;0.8282329060895002;9.548481544818586;1315.1089846810005;6.7325511899570465;0.04401551419602758;0.7595439928109722;[MPP1, PRTFDC1]
GO:1900477;negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter;12.0;1.0;0.9481203125901445;9.628524252492122;2198.127652685899;9.777073627680469;0.07356935434894436;0.9481203125901445;[NACC2]
GO:0071471;cellular response to non-ionic osmotic stress;6.0;1.0;0.8231203125901445;9.628524252492122;98.58922030228089;9.777073627680469;0.0032996924789795543;0.8231203125901445;[PTGS2]
GO:1904707;positive regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.75549718811011;6.444869117505266;0.0027028138156570515;0.6805102716434839;[MMP9, GNAI2, PAK1]
GO:0071354;cellular response to interleukin-6;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[PID1, ST3GAL6]
GO:0045076;regulation of interleukin-2 biosynthetic process;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;155.28197644939593;6.8867018697843045;0.005197148007055472;0.7031056191423581;[LAG3, CARD9, CD3E, CD4, CD28]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, MCM7, GMNN, SKP2, DBF4, CCNE1, MCM3, MCM4, RHOU, MCM6, MCM2, PRIM1, IQGAP3, RBBP8, RANBP1, CDKN2C, PLK2, RPA1, CDC6, INHBA, POLA1, POLA2, WEE1, NASP, POLE2, RPA3]
GO:0140058;neuron projection arborization;8.0;0.8436909121759173;0.7968454560879586;9.420884887713877;64.60914726719044;7.57984905034425;0.0021624100145753813;0.7626338329336335;[NRP1, NLGN1, LRRK2]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHI3L1, XCL1, CCL13, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, CCL20]
GO:0050779;RNA destabilization;8.0;0.8653626801206646;0.8076813400603323;9.557065288509976;620.8520178043873;6.518977089658987;0.020779358305372676;0.7083807915285978;[TNFRSF1B]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[PPP2R1A, PFKFB4, PTPRE, ALPL, PTPRR, PTPRK, IMPA2, DUSP2, DUSP1, DUSP6, ACPP, FBP1, TPTE, NT5E, PPP1CA]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[NLGN1, LRRK2]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[AKT1, MEF2C, F2R, MSH2, NAIP, C5AR1, SLC30A10, CORO1A, WFS1, NR4A2, NRP1, LRRK2, CHL1, LRP1, GPNMB, CCL2, GABRA5]
GO:0035050;embryonic heart tube development;5.0;1.0;0.7902410118609202;9.628524252492122;33.009488292418915;7.004484905440688;0.0011047978665365144;0.6484506956670166;[HHEX]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[CXCL13, SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, ATP1B1, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, CAV1, CXCL10, CXCL11, CXCL12, CD24, GPR18, CXCL9, ATP2A3, FASLG, GRM5, CCR9, CCR6, CD36, CCR5, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, XCL1, CX3CR1, SLC24A1, CCL13, SLC24A4, PTGER2, CXCR5, CXCR4, CXCR6, CCL8, CXCR1, CCL7, SV2A, CCL5, CXCR2, S1PR3, CCL1, CCL19, GPR157, CCL23, TMEM64, GPR6, P2RX5, CD4, GRINA, F2RL3]
GO:0060337;type I interferon signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.587418885654044;0.00101047745553359;0.6366602269110988;[IFNA5, IFNA4, IFNA7, IFNA2, SAMHD1, IFNA8, IFNA21, EGR1, IFNA14, IFNA16, IFNA10]
GO:0002399;MHC class II protein complex assembly;7.0;1.0;0.8509193652572005;9.628524252492122;45.61567929762514;9.777073627680469;0.0015267157346454312;0.8509193652572005;[HLA-DMB]
GO:0045086;positive regulation of interleukin-2 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.292166977892469;0.027942676825076673;0.747921758369865;[CD4, CD28, CD3E]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[CXCL6, CXCL9, HMGB2, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, PYCARD, EDNRB, CTSG, CD36, CCR5, HAVCR2, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, ADAM9, TLR4, CX3CR1, CD274, CEBPE, KLRK1, STAP1, NLRP3, CCL2, ABCA1, CCL20, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2, PPBP, CXCL10, CXCL11, PF4]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, PADI4, NAIP, LY9, KLRK1, SLAMF7, IGHA1, LYN, KIR2DS1, KIR2DS2, SH2D1A, KIR2DS4, KIR2DS5, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, HAVCR2, ANXA1, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, CARD9, KIR3DL1, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, CD6, PTX3]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, LYN, DUSP1, DUSP6, NLRP12, TLR4, ATF3]
GO:0045088;regulation of innate immune response;6.0;0.4673148936341128;0.556777759407201;6.780712109014753;42.469229973879315;3.8881956693475885;0.0014214069074002054;0.52196281994017;[ICAM2, BTK, KLRK1, LYN, SH2D1A, MARCO, CTSS, FFAR2, MUC15, CD36, HAVCR2, ARG1, FCRL3, MMP12, TLR1, NCR1, CEACAM1, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, PAK1, NR1H2, CARD9, LILRB1, LGR4, PYCARD, IL18RAP, LAG3, CD180, CLEC4D, S100A8, LY96, CAV1, ITGAM, HMGB2, CR1, IFNG, LTF, COLEC12, UNC93B1, CLEC12B, NLRC4, SAMHD1, CCL5, FCGR2B]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, TNFSF11, PDGFRB, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, HAVCR2, KIT, CHI3L1, XCL1, CCL13, GNAI2, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, TIE1, CD4, TEK]
GO:0071103;DNA conformation change;5.0;0.6729672293956388;0.6267246265587396;8.242229891372231;21.24116723228514;5.058574756385375;7.10922751455178E-4;0.5489367601502517;[MCM7, NCAPG2, HMGB2, SMC4, SMC2, HHEX, RUVBL1, ANXA1, MCM4, MCM6, MCM2, BLM, RAD54B, HMGA1, RPA1, RAD51, ACIN1, NCAPD2, NCAPD3]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[EGR1, IL1R1, IL1R2]
GO:1904694;negative regulation of vascular smooth muscle contraction;9.0;0.9326813400603323;0.8625812952104552;9.593432932680852;290.18102098946144;8.67846133901236;0.009712097626553416;0.8400575416471059;[DOCK5]
GO:0045806;negative regulation of endocytosis;7.0;0.7192862368539868;0.710562483684194;9.057979394024509;124.57926064357885;5.8650506222523235;0.004169555739685066;0.6508583268319309;[MCTP1, LGALS3, TGFB1, NR1H2, CAV1, LILRB1, PRTN3, FCGR2B, EPHA3, TLR2]
GO:0043507;positive regulation of JUN kinase activity;13.0;0.8653626801206646;0.8952363048279688;9.582714716460828;4931.413721535565;5.459585514144159;0.16504997927558432;0.7417584218576596;[TNFSF11, MAP4K1, TNFRSF11A, PAK1, CCL19, FZD5, PKN1]
GO:0061052;negative regulation of cell growth involved in cardiac muscle cell development;10.0;1.0;0.9152410118609203;9.628524252492122;1870.595370074125;8.16763571524637;0.0626071436098452;0.8329342821725234;[PAK1]
GO:2001170;negative regulation of ATP biosynthetic process;11.0;0.8436909121759173;0.8542744084176208;9.548481544818586;2736.7575067278403;7.069023426578259;0.09159681082833118;0.7939391391080821;[PID1, FBP1]
GO:1903125;negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;564.5007788811621;9.777073627680469;0.018893333051434806;0.9152410118609203;[LRRK2]
GO:2001171;positive regulation of ATP biosynthetic process;11.0;0.8653626801206646;0.8651102923899945;9.574457031221845;2732.5785771167416;6.481236761676141;0.09145694581504019;0.7638797017301124;[PFKFB4, PID1]
GO:0042534;regulation of tumor necrosis factor biosynthetic process;7.0;0.8933024483968273;0.7975705894556142;9.523163736834295;157.07373591862395;6.832634648514029;0.005257116584011703;0.7003406189322132;[GHSR, CARD9, LILRB1, AZU1, TLR1, TLR4, CCR2]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[TLR1, AZU1, TLR4, CCR2]
GO:0006203;dGTP catabolic process;12.0;1.0;0.9481203125901445;9.628524252492122;7925.687620454256;8.67846133901236;0.26526563200083675;0.8919372290569614;[SAMHD1]
GO:1990001;inhibition of cysteine-type endopeptidase activity involved in apoptotic process;13.0;1.0;0.9625549647676366;9.628524252492122;2010.8653136723324;7.292166977892469;0.06730185238732382;0.8354767231375014;[NLRC4, NAIP]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, NRP1, CDKN1A, PPP2R1A, TNR, DCC, PSRC1, FBP1, PAK1, TGFB1, CDKN2C, SEMA4B, INHBA, BCL6, SIPA1]
GO:0010811;positive regulation of cell-substrate adhesion;5.0;0.7980440201809971;0.6892630219514189;9.0094850440859;35.30989762708448;5.049685808968129;0.0011817904967337807;0.5484821789659555;[DOCK5, NRP1, EMILIN2, CD36, OLFM4, DNM2, CEACAM6, COL8A1, FLNA, JUP, TEK]
GO:0019521;D-gluconate metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;93.14631879483512;9.083926447120524;0.0031175234638186767;0.839552420951524;[PGD]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, HLA-DPA1, LAG3, DNM2, HLA-DQB1, HLA-DMA, HLA-DMB, RACGAP1, HLA-DQA1, HLA-DRB4, HLA-DPB1, HLA-DRA, FCGR2B]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[LRRK2, PTGS2, CDH1, TGFB1, JUP, IFNG]
GO:1902041;regulation of extrinsic apoptotic signaling pathway via death domain receptors;9.0;0.8259837884571596;0.8092325194088689;9.485423408851448;64.8607677845634;5.734022359845919;0.0021708315268480906;0.6894787953221185;[HMGB2, FASLG, LGALS3, TNFRSF10B, MAL, ATF3]
GO:0090501;RNA phosphodiester bond hydrolysis;7.0;0.6369964171292115;0.6694175738218062;8.663443356448536;229.5272768035792;4.7664383335842135;0.007682071393477758;0.5946752432987477;[RNASE6, RNASE3, RNASE2, EXO1, SAMHD1]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, SPINT2, CDH5, CDH3, CDH1, MEF2C, ACTN1, CLDN3, SLC1A3, ST14, BCL11B, BCL6, NOX4, NRP1, PDPN, SLITRK6, FLNA, TEK]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, TNFSF11, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CAV1, CD3G, CD3E, KCND2, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, RAD51, P2RX1, RBMX]
GO:0006212;uracil catabolic process;9.0;1.0;0.896240625180289;9.628524252492122;1126.0761526232816;9.083926447120524;0.03768875542555955;0.8607930461318132;[DPYD]
GO:1904469;positive regulation of tumor necrosis factor secretion;10.0;1.0;0.9152410118609203;9.628524252492122;775.9675723657698;7.292166977892469;0.025970936321606315;0.7881627702307852;[ORM1, FZD5, LRRK2, HAVCR2]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CDKN1A, BRCA2, PYCARD, SFN, MLH1, TNFRSF1B, MSH6, MSH2]
GO:0042663;regulation of endodermal cell fate specification;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;108.59969873383258;8.390779266560578;0.0036347341832379046;0.8041048419030481;[DUSP6]
GO:0006210;thymine catabolic process;9.0;1.0;0.896240625180289;9.628524252492122;1047.620013338454;8.67846133901236;0.03506289904963761;0.8400575416471059;[DPYD]
GO:0006337;nucleosome disassembly;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;96.25424468242052;6.832634648514029;0.0032215429463244545;0.6725415662651573;[NFE2, SMARCD3, HMGA1]
GO:0006334;nucleosome assembly;7.0;0.8653626801206646;0.7836007053175329;9.474373572664863;104.51542930890014;4.99795013456894;0.0034980373611892576;0.6065147675675062;[HMGB2, CHAF1B, CHAF1A, RUVBL1, BRD2, PADI4, MCM2, HIST1H2BK, H1FX, NASP, CENPK, CENPL]
GO:0006214;thymidine catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;2915.381228856312;9.777073627680469;0.09757518605705806;0.9152410118609203;[DPYD]
GO:0097011;cellular response to granulocyte macrophage colony-stimulating factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.57984905034425;0.0027327542132076126;0.710754145523778;[CD4, AKT1]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, PYCARD, STMN1, PDGFRB, MEF2C, PFN1, EPHA3, TACSTD2, CORO1A, STAP1, TGFB1, BST1, CXCL12, NOX4, NRP1, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, TMEFF2, RHOU, LRP1, PAK1, EPS8L1, FLNA, JAM3, GSN, TEK]
GO:0072173;metanephric tubule morphogenesis;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;32.20947323359611;8.16763571524637;0.0010780220824845236;0.7408135829017477;[CXCR2, LGR4]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[NRP1, ARHGEF10L, CTGF, PAK1, NOX4]
GO:0010944;negative regulation of transcription by competitive promoter binding;11.0;1.0;0.9324289523296623;9.628524252492122;1584.3015218227836;7.57984905034425;0.053025146156608326;0.8200627852632958;[HHEX, DACH1]
GO:0030890;positive regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.1565706318756;6.063501560976162;0.016940604907709607;0.706328376990269;[CDKN1A, TFRC, TNFSF13B, MEF2C, FCRL3, MSH6, BST1, BCL6, CD320]
GO:0016485;protein processing;6.0;0.6519675769143192;0.6491041010473041;8.320191432841943;99.81063536400724;4.720827822332161;0.0033405721418933456;0.564543666965156;[CTSS, CTSG, MME, HM13, PSEN2, ACE, DHCR24]
GO:0031622;positive regulation of fever generation;9.0;0.8436909121759173;0.8180860812682478;9.454170865347344;276.00155245721845;7.8311634786251565;0.009237523575472428;0.7967266896635242;[CNR1, TNFSF11, TNFRSF11A, PTGS2]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[CALCRL, LRP1, TFRC, CXCR1, CXCR2, CD36, AP2M1, CAV1, LILRB1, DNM2, CEACAM1, CD9, RAMP1]
GO:1902176;negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway;10.0;0.8653626801206646;0.8479223519212526;9.600353375525426;999.3623287810346;6.781341354126479;0.033447757776597226;0.7620391240755716;[VNN1, AKT1]
GO:0014041;regulation of neuron maturation;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;97.4678129670593;7.697632086000634;0.0032621599846707665;0.7686572628545723;[EDNRB, LRRK2]
GO:0051272;positive regulation of cellular component movement;5.0;0.5452700253111464;0.5628760245164934;7.377232453885626;52.22589589123734;3.603287523778533;0.0017479537352249267;0.4745133033969606;[LGALS3, STMN1, C3AR1, AKT1, IL1R1, ACTN4, CLDN7, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, CCR1, TNFSF14, PLK2, PPBP, PTK2, NOX4, NRP1, NRP2, CCR6, CCR2, ANXA1, ANXA3, GAB1, TACR3, CEACAM6, KIT, HBEGF, PTAFR, PTGS2, GNAI2, PAK1, GPNMB, CXCR2, PDPN, FLNA, CCL19, CCL20, PF4, CXCL13, SLC8A1, CXCL16, PYCARD, IL6R, PDGFRB, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, CXCL10, CXCL11, CXCL12, BCL6, DOCK5, CXCL6, CXCL9, TNFAIP6, LAMC2, CXCL1, CXCL3, CXCL2, CXCL5, MMP9, IFNG, XCL1, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL1, EGF, SEMA4B, TEK]
GO:2001190;positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell;9.0;1.0;0.896240625180289;9.628524252492122;413.7426732268016;9.083926447120524;0.013847594928669781;0.8607930461318132;[HLA-DMB]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, FZD5, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, PF4, PLXND1, FOXO1, CXCL10, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, TNFSF11, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, TLR4, TLR2, LILRB1, ARID4A, ADRB2, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, DLL1, MEIS2, RBMX]
GO:0006664;glycolipid metabolic process;6.0;0.6023560406934092;0.6242983329368491;8.337540071176557;77.09560371581999;5.152100814396198;0.002580320474829782;0.586598987835556;[B3GNT5, KIT, ST3GAL6]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, NAIP, LRP1, C5AR1, SLC30A10, CORO1A, CCL2, WFS1, GABRA5, NR4A2]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, GHSR, ANXA1, DUSP1, ANXA3, ARG1, AVPR1A, ADAM9, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL, SDC1]
GO:2001189;negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell;9.0;1.0;0.896240625180289;9.628524252492122;430.8793777811617;8.67846133901236;0.014421145008071396;0.8400575416471059;[LGALS3, LILRB1, HAVCR2]
GO:0044869;negative regulation by host of viral exo-alpha-sialidase activity;10.0;1.0;0.9152410118609203;9.628524252492122;511.145923051964;9.083926447120524;0.017107594043084314;0.8797934328124444;[PTX3]
GO:0038123;toll-like receptor TLR1:TLR2 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.67846133901236;0.013811191226989502;0.8919372290569614;[TLR1, TLR2]
GO:0043651;linoleic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;192.24999652429597;6.943860283624253;0.006434434369904319;0.7513499630073597;[ACSL1]
GO:0032933;SREBP signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;1530.9942493681936;7.8311634786251565;0.051240999720983706;0.8486063770733797;[ARHGEF10L]
GO:0051152;positive regulation of smooth muscle cell differentiation;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;145.28799013580416;7.292166977892469;0.004862658279143298;0.7238411236270654;[TGFB1, SMARCD3, KIT, ENG]
GO:0042692;muscle cell differentiation;4.0;0.6873818243518346;0.5936909121759173;8.242229891372231;21.066225782797595;5.382624473008031;7.050676185779127E-4;0.525267665867267;[POPDC3, SMARCD3, EDNRB, AKT1, MEF2C, SORT1, AVPR1A, NOX4, SIK1]
GO:0019731;antibacterial humoral response;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;115.72816977122699;6.221725566191056;0.0038733176936520722;0.6690987000520388;[IGHM, DEFA4, HIST1H2BK, RNASE6, RNASE3, DEFA1, SLPI, CTSG, IGHA1, IGKV3-20, CAMP, LTF]
GO:0019730;antimicrobial humoral response;5.0;0.8259837884571596;0.7032329060895001;9.292052015870908;43.185159168215264;5.132682728539097;0.0014453684132401858;0.5527266452925662;[IGHM, CXCL6, CCL13, CXCL9, HIST1H2BK, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, CTSG, IGHA1, ELANE, CAMP, DEFA4, SLC11A1, RNASE6, RNASE3, AZU1, DEFA1, PPBP, LYZ, CXCL10, CXCL11, SLPI, LCN2, PRTN3, BPI, IGKV3-20, S100A8, LTF, PF4]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176B, TMEM176A, LILRB1, FCGR2B]
GO:0060168;positive regulation of adenosine receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;237.90608858864195;8.67846133901236;0.007962502683482768;0.8188169164668168;[ACPP]
GO:0060161;positive regulation of dopamine receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.311553696747;8.16763571524637;0.007976073235756139;0.7926932703116032;[LRRK2]
GO:0009750;response to fructose;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;32.95598622603122;7.697632086000634;0.001103007200523252;0.7445766281117727;[PTGS2]
GO:1902231;positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;829.8707423181995;7.8311634786251565;0.027775026910210696;0.8157270763441555;[NACC2]
GO:1903206;negative regulation of hydrogen peroxide-induced cell death;9.0;0.8436909121759173;0.8180860812682478;9.589303539338841;500.078557460717;6.8867018697843045;0.01673717927672765;0.7484268790654467;[GPR37, LRRK2]
GO:1902236;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;830.7594506111926;6.832634648514029;0.02780477117699164;0.7646622655359331;[WFS1, LRRK2, GRINA]
GO:0061017;hepatoblast differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;47.57053087451796;9.083926447120524;0.0015921428576718348;0.7547934328124444;[HHEX]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[NRP1, LRRK2, TNR, DCC, NLGN1, LRP1, LINGO1, PLK2, SEMA4B, PTK2, ITM2C]
GO:0010738;regulation of protein kinase A signaling;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;45.070113835906206;6.599019797332524;0.001508456149618737;0.6883935445785896;[LRRK2, ADRB2]
GO:0019322;pentose biosynthetic process;6.0;0.8259837884571596;0.7361122068187242;9.360260265897443;135.4172465659101;8.390779266560578;0.004532293374951417;0.7522251544931926;[PGD]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[CELSR1, CDH3, AP2M1, TLE4, CCNE1, PFN1, APCDD1, FZD5, NR4A2, VANGL1, SDC1, CD24, CDK14, LRRK2, HHEX, AES, EGF, TMEM64, LGR4]
GO:0032760;positive regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.9095484537234;5.587418885654044;0.002875315273172136;0.6366602269110988;[ORM1, LRRK2, PYCARD, CD36, CCR2, HAVCR2, TLR1, TLR4, TLR2, PTAFR, LY96, CCL19, FZD5, CARD9, AZU1, CD2, PF4]
GO:0032764;negative regulation of mast cell cytokine production;8.0;1.0;0.875;9.628524252492122;311.05347994333346;9.083926447120524;0.010410680043746014;0.839552420951524;[BCL6]
GO:0010971;positive regulation of G2/M transition of mitotic cell cycle;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;355.9636244052406;6.481236761676141;0.011913782162380092;0.7276913745807394;[SMARCD3, RAD51C]
GO:0061001;regulation of dendritic spine morphogenesis;11.0;0.8933024483968273;0.8790801765280758;9.548481544818586;263.40314350006116;6.166155715036245;0.00881586616550832;0.747766442352181;[NLGN1, LRRK2]
GO:1903217;negative regulation of protein processing involved in protein targeting to mitochondrion;11.0;1.0;0.9324289523296623;9.628524252492122;1717.571539060114;9.083926447120524;0.057485573698313114;0.8969813732811862;[LRRK2]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[, HP, CXCL13, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, KLRK1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, PPBP, LYZ, IGKV3-20, IGHM, CXCL6, HMGB2, CTSG, CD36, CAMP, HAVCR2, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, NLRC4, IGKC, CCL20, CARD9, CD4]
GO:0071284;cellular response to lead ion;6.0;1.0;0.8231203125901445;9.628524252492122;77.8106912628645;8.390779266560578;0.002604253811492351;0.7522251544931926;[PTGS2]
GO:0030217;T cell differentiation;6.0;0.657518819034173;0.651879722107231;8.679443697794976;65.04859315339479;5.132682728539097;0.00217711787291102;0.5856059460217904;[CD3G, CD3E, CCR9, CCR6, ANXA1, RUNX2, CLEC4D, KIT, BLM, EGR1, TGFB1, BCL11B, FZD5, BMX, CD4, CD28, GPR18, IL18R1]
GO:0010508;positive regulation of autophagy;7.0;0.7192862368539868;0.710562483684194;9.040737587590003;216.89043707272492;5.132682728539097;0.007259127740103463;0.6134049986888465;[LRRK2, TSC2, IFNG, ADRB2, FOXO1, PLK2]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[TMEM100, HHEX, FCER2, PSEN2, DLL1, S1PR3, TGFB1, JAG1, KRT19]
GO:0071287;cellular response to manganese ion;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;77.8106912628645;7.57984905034425;0.002604253811492351;0.710754145523778;[LRRK2]
GO:0019432;triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;411.96489591296563;6.832634648514029;0.013788094321871398;0.7244212536750128;[DGAT2, ACSL1, MOGAT2]
GO:0010621;negative regulation of transcription by transcription factor localization;11.0;0.9326813400603323;0.8987696223598284;9.604426700913061;1614.1306916489104;8.67846133901236;0.05402350162617884;0.8762458687964789;[HHEX]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, CCL5, AKT1, CCL2, LYN, TGFB1, CD6, TLR4, TLR2]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[, AKT1, STK32B, MAP2K2, VRK1, PLK2, LRRK2, MAP4K1, SGK1, CAMK4, PKN1]
GO:0031666;positive regulation of lipopolysaccharide-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;344.2408759115043;7.697632086000634;0.011521432320083432;0.7445766281117727;[CD180, LY96]
GO:0032755;positive regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.94897299966192;5.395046993006588;0.0021737836760178982;0.5990232667078439;[PYCARD, CD36, IL6R, F2R, TLR1, TLR8, TLR7, TLR4, TLR2, PTAFR, CARD9, LILRB2]
GO:0019557;histidine catabolic process to glutamate and formate;10.0;1.0;0.9152410118609203;9.628524252492122;1180.4378706775767;8.390779266560578;0.03950819320646687;0.8443458537639685;[HAL]
GO:0048294;negative regulation of isotype switching to IgE isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1408.9297354134765;8.67846133901236;0.047155610289849756;0.8762458687964789;[BCL6]
GO:0019556;histidine catabolic process to glutamate and formamide;10.0;1.0;0.9152410118609203;9.628524252492122;1160.0488469910097;8.390779266560578;0.038825790932607476;0.8443458537639685;[HAL]
GO:0042759;long-chain fatty acid biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.372590878354922;458.549617088559;6.375876246018314;0.015347243016091356;0.722303232910233;[ELOVL6, PTGS2, ALOX5, PLP1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[CAV1, PTAFR, F2R, AVPR1A, PTGS2, AKT1]
GO:1903464;negative regulation of mitotic cell cycle DNA replication;11.0;0.8933024483968273;0.8790801765280758;9.57973408832269;1479.2060550404028;9.083926447120524;0.049507695463181504;0.8969813732811862;[BCL6]
GO:1902499;positive regulation of protein autoubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;610.7263414608234;9.083926447120524;0.020440461030670667;0.8969813732811862;[LRRK2]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[CYFIP1, AKT1, GHSR, CEACAM1, FOXO1, PAK1]
GO:0032507;maintenance of protein location in cell;5.0;0.6763753087927167;0.6284286662572787;8.412128928167629;43.86076268124676;5.4730085344763;0.0014679802548176633;0.5701309228349632;[AKT1, TLN1, BARD1, GSN, JUP, CAV1, CD4]
GO:0010955;negative regulation of protein processing;9.0;0.7192862368539868;0.7558837436072825;9.27570287786938;707.1969765737138;6.039404009397101;0.023669246369964203;0.705096027081865;[LRRK2, NLRC4, CR1, IL1R2, NAIP]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, EGF, TMEM64, NR4A2, SDC1, LGR4]
GO:0019546;arginine deiminase pathway;11.0;1.0;0.9324289523296623;9.628524252492122;560.9534287236577;9.777073627680469;0.018774606434071004;0.9324289523296623;[PADI4]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, PAK1, FLNA, CXADR, ANXA1, GAB1, KIT]
GO:1903351;cellular response to dopamine;8.0;1.0;0.875;9.628524252492122;545.6259493406901;7.138016298065211;0.018261609492958953;0.7400384854347593;[LRRK2, DNM2]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2C, PADI4, ATF3, EZH2, CHAF1B, FLNA, ZNF467, ATAD2, PKN1, RUVBL1, FOXO1, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, BTK, EGR1, EGR2, EGR3, HMGA1, MXD1, HMGB2, AFF3, NUP62, CREB5, EHF, HOXA9, MYB, NFE2, ZNF367, BRD2, PAWR, PAX5, AES, GTF2H1, TLE4, NACC2, BCL6, CNOT3, MAFF, RFC1, SMARCD3, CEBPE, KLF8, KLF5, ZNF608, EBF1, BCL11B, BCL11A, ARID4A, C5AR1, NLRP3, CBX4, NR4A2, LTF, MEIS2, RBMX]
GO:0006112;energy reserve metabolic process;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;30.85741402911629;5.618190544320798;0.0010327698776848686;0.5775555375700647;[PID1, PPP1R3A, PYGL, AKT1, PPP1CA]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NUP107, SLA2, SPIB, AKT1, ATF3, JAG1, JUP, PKIG, CHAF1B, MMP12, PTAFR, ZNF467, ATAD2, PKN1, LGR4, GMNN, BLM, CIITA, HHEX, E2F5, E2F7, POU2AF1, TNFSF11, FBXO5, BTK, TGFA, EGR1, EGR2, EGR3, POLA1, KIT, PCNA, NR3C2, CAV1, TCF4, MXD1, NUP133, FBP1, CD4, NUP85, NFE2, CDKN1A, ZNF367, EPCAM, NR1H2, PF4, PLXND1, TLE4, MAP2K2, BCL6, CCDC22, SLC26A3, RFC1, XCL1, CEBPE, NLRC4, PPIL4, PPP2R1A, FLT3LG, SIK1, IFNA2, PRL, XPO1, MLF2, TLR4, TLR2, NLRP3, CBX4, SLC40A1, DNM2, LTF, RBMX, PID1, EHMT2, MEF2C, PADI2, PADI4, EZH2, FLNA, RUVBL1, S100A8, MAZ, TNFRSF11A, FOXO1, CXCL10, FASLG, CCNH, TMPO, PCBP3, CD28, PTPRK, BRCA2, CD36, NLRP12, CCNE1, HMGA1, INHBA, HMGB2, ARHGEF10L, AFF3, NUP62, PSRC1, CREB5, EGF, NUP35, RAN, EHF, HOXA9, MYB, ELANE, FZD5, CDC6, HAVCR2, BRD2, ANXA3, NFAM1, PAWR, PAX5, AES, ENG, GTF2H1, PYCARD, DACH1, CDH1, F2R, NACC2, WFS1, CNOT3, MAFF, SMARCD3, RBBP8, KLF8, KLF5, ZNF608, EDNRB, CHEK1, SLC11A1, EBF1, RUNX2, PFN1, BEX1, SP140, BCL11B, BCL11A, RHOG, SGK1, LILRB1, CAMK4, ARID4A, BASP1, ADRB2, TGFB1, NR4A2, NR4A1, TMEM100, CKAP2, TGFBR3, IFNG, DLL1, MEIS2]
GO:0009620;response to fungus;5.0;0.7586651285174919;0.6695735761196662;9.089527751759436;27.267803904038782;5.926926025970411;9.126288572378991E-4;0.5933442844592942;[TGFB1, DEFA4, CARD9, DEFA1, CTSG, PTX3, TLR4, ELANE, S100A8, LTF]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[CHRM2, LHCGR, CHRM1, C5AR1, F2R, FPR1, FPR3, FPR2, GPR84, NMBR, MC3R, GRM5, P2RY6, EDNRB, P2RY2, CXCR2, C3AR1, AGTR1, F2RL3]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[PID1, EHMT2, SLA2, SPIB, AKT1, MEF2C, ATF3, JAG1, JUP, PKIG, EZH2, MMP12, PTAFR, ZNF467, ATAD2, PKN1, RUVBL1, MAZ, FOXO1, CXCL10, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, TGFA, PCBP3, EGR1, EGR2, EGR3, CD28, CD36, KIT, NR3C2, CCNE1, CAV1, HMGA1, INHBA, TCF4, MXD1, HMGB2, ARHGEF10L, FBP1, CREB5, EHF, HOXA9, MYB, ELANE, NFE2, FZD5, CDKN1A, ZNF367, HAVCR2, BRD2, PAWR, PAX5, AES, ENG, EPCAM, NR1H2, GTF2H1, PF4, PLXND1, DACH1, TLE4, NACC2, WFS1, BCL6, MAFF, RFC1, SMARCD3, CEBPE, RBBP8, KLF8, KLF5, PPIL4, ZNF608, EDNRB, CHEK1, SLC11A1, EBF1, FLT3LG, RUNX2, PFN1, BEX1, BCL11B, BCL11A, PRL, XPO1, TLR4, TLR2, LILRB1, ARID4A, ADRB2, NLRP3, TGFB1, CBX4, NR4A2, NR4A1, SLC40A1, TMEM100, CKAP2, TGFBR3, IFNG, DLL1, MEIS2, RBMX]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[CXCL13, SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CXCL10, CXCL11, CD24, GPR18, CXCL9, FASLG, CCR9, CCR6, CD36, CCR5, CCR2, CD52, PTGIR, TRPC1, AVPR1A, XCL1, CX3CR1, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, S1PR3, CCL1, CCL19, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CX3CR1, CXCL6, CCL13, CXCL9, CXCR5, CXCR4, CXCL1, CXCR6, CXCL13, CXCL3, CXCL2, CXCL5, CCL8, CXCR1, CCL7, CCL5, CXCR2, CCRL2, CCL4, CCR9, CCL2, CCL1, CCR6, CCL19, CCR5, CCL18, CCR10, CCR2, CCR1, CCL23, CCL20, PPBP, CXCL10, CXCL11, CXCL12, XCL1, PF4]
GO:0090336;positive regulation of brown fat cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;143.10318807846457;7.57984905034425;0.004789534920478337;0.738553198190834;[PTGS2]
GO:0045408;regulation of interleukin-6 biosynthetic process;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;154.99429437694414;7.069023426578259;0.005187519546987567;0.7124295520356204;[TLR1, GHSR, NLRP12, PTAFR, CARD9]
GO:0030031;cell projection assembly;4.0;0.6729672293956388;0.5864836146978194;8.124446855715847;35.515967283127445;3.9749552523034066;0.0011886874626708887;0.45327939645711923;[CYFIP1, NUP85, NRP1, EMP1, KIT, RHOU, FGD4, FLNA, SH2B1, GSN, KLF5]
GO:0042495;detection of triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;192.9668546023468;9.083926447120524;0.006458426964646296;0.839552420951524;[TLR1, TLR2]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA1, ANXA3, GAB1, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, PTGS2, DLL1, CXCR2, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0034629;cellular protein-containing complex localization;5.0;0.7043150770688792;0.6423985503953599;8.616923340813642;38.207100950210915;6.599019797332524;0.0012787572846451128;0.6277151911823093;[, SEH1L, NUP133, NACC2]
GO:0019483;beta-alanine biosynthetic process;8.0;0.8653626801206646;0.8076813400603323;9.523163736834295;476.973390255232;9.083926447120524;0.015963870123660538;0.839552420951524;[DPYD]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[MSH2, MAFF, PTPRR, TMEM100, HHEX, TIE1]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, JAG1, JUP, MMP12, ATAD2, LGR4, BLM, FOXO1, CXCL10, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, EGR1, EGR2, EGR3, CD28, BRCA2, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, EGF, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAX5, ENG, EPCAM, NR1H2, GTF2H1, PF4, PLXND1, CDH1, MAP2K2, F2R, MAFF, RFC1, SMARCD3, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, ADRB2, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, DLL1, MEIS2, RBMX]
GO:0044320;cellular response to leptin stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;109.38485831558611;7.379178354882098;0.003661012767841448;0.7004918368257019;[PID1]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[ST6GALNAC2, ASGR1, ASGR2, ST3GAL6]
GO:0031116;positive regulation of microtubule polymerization;10.0;0.8933024483968273;0.861892236059334;9.589303539338841;431.61701704611926;6.518977089658987;0.014445833130437288;0.7486218033895181;[PAK1, PSRC1]
GO:0034504;protein localization to nucleus;6.0;0.7192862368539868;0.682763431017138;8.763526815005518;32.77360880529348;4.8942717050940985;0.001096903192380182;0.5734135951955668;[NUP107, CSE1L, HHEX, XPO1, NUP62, NUP133, TSC2, MMP12, NUP54, NUP85, NUP88, RANBP1, NUP155, NUP35, RAN]
GO:0030260;entry into host cell;6.0;0.7369933605727446;0.6916169928765168;8.68406264365127;26.98811751292015;5.212725436212633;9.032680054285688E-4;0.5896993338145817;[SCARB2, TFRC, CDH1, ANPEP, CLEC5A, ITGB6, CCR5, CR2, CR1, CXADR, GYPA, CXCR4, NCAM1, GPR15, CD4]
GO:0007264;small GTPase mediated signal transduction;6.0;0.7369933605727446;0.6916169928765168;8.741221057491218;26.42836680105094;4.015022244900292;8.845336528452411E-4;0.5284487369119741;[CYFIP1, CELSR1, GRAP2, RAB32, DOK3, AGTR1, IQGAP3, RASGRP4, PLK2, DHCR24, BCL6, RGL4, RGL1, LAT, DOCK5, CDKN1A, ARHGAP6, RALGPS2, RHOG, RHOU, PAK1, PDPN, EPS8L1]
GO:1905279;regulation of retrograde transport, endosome to Golgi;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;61.70798243857084;8.67846133901236;0.0020653106386403163;0.7947362817240173;[LRRK2]
GO:0045410;positive regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.3044735649636;7.8311634786251565;0.02792341990494083;0.7754860644832351;[TLR1, PTAFR]
GO:0007265;Ras protein signal transduction;7.0;0.7586651285174919;0.7302519295159464;8.935377071932177;27.526979089716047;4.2636448815154875;9.213032174599934E-4;0.5689623627776663;[CYFIP1, CELSR1, GRAP2, RAB32, DOK3, AGTR1, IQGAP3, PLK2, DHCR24, BCL6, LAT, CDKN1A, ARHGAP6, RHOG, RHOU, PAK1, PDPN, EPS8L1]
GO:0045773;positive regulation of axon extension;11.0;0.8933024483968273;0.8790801765280758;9.582004236857228;1257.908905926367;6.113511981550823;0.04210107903683872;0.7450742393735527;[CYFIP1, NRP1, PAK1, CXCL12]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[CELSR1, ARHGAP6, PAK1, PDPN, EPS8L1, RHOG, BCL6, AGTR1, RHOU]
GO:0042147;retrograde transport, endosome to Golgi;6.0;0.8653626801206646;0.7558016526504768;9.36615998802463;84.48667651462847;5.311165509025885;0.0028276930298722367;0.5947335637161829;[EVI5]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[PID1, TSC2, SLA2, PTPRE]
GO:0043117;positive regulation of vascular permeability;6.0;1.0;0.8231203125901445;9.628524252492122;22.58320658440663;7.474488534686424;7.558396008136816E-4;0.7053660038532718;[TGFB1, CXCR2]
GO:0045657;positive regulation of monocyte differentiation;9.0;1.0;0.896240625180289;9.628524252492122;840.3783565179247;7.57984905034425;0.02812670730123667;0.7838744581139225;[CD4, ACIN1]
GO:0001953;negative regulation of cell-matrix adhesion;7.0;0.8653626801206646;0.7836007053175329;9.387362195675234;66.9585131603638;6.280566066213989;0.002241041176727861;0.6721078059595746;[JAG1, ARHGAP6, BCL6]
GO:1990776;response to angiotensin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;7.138016298065211;0.0024778305216419678;0.7159578506919597;[CDC6, PTGS2, SLC30A10]
GO:0010666;positive regulation of cardiac muscle cell apoptotic process;10.0;1.0;0.9152410118609203;9.628524252492122;149.5070754231924;7.474488534686424;0.005003867266781941;0.7974867031240476;[CXCR2]
GO:0018146;keratan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;415.40755540718914;6.409777797693995;0.013903317036950667;0.7027963346592216;[OGN, ST3GAL6]
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8259837884571596;0.845420846558242;9.498471124243924;3778.5456327194074;5.334422371190153;0.12646452185682636;0.705231560468336;[LRRK2, AKT1, PLK2, CAV1]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[PTGS2, KLRK1, AKT1, CD36, DNM2, IFNG, PTX3, TLR4]
GO:0090314;positive regulation of protein targeting to membrane;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;497.0805077511855;6.343086423195323;0.016636837251019197;0.7396267465268138;[, ITGAM, PAK1]
GO:1905289;regulation of CAMKK-AMPK signaling cascade;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;47.267338413241674;9.777073627680469;0.0015819952788484175;0.875;[LRRK2]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[FASLG, IL6R, DCC, TNFRSF1B, IFNG, TGFB1, SORT1, TNFSF12, G0S2, TNFRSF10B, INHBA]
GO:0006145;purine nucleobase catabolic process;8.0;0.7980440201809971;0.7740220100904985;9.464221201200845;915.7889644076664;8.390779266560578;0.030650632482165402;0.8041048419030481;[DPYD]
GO:0045786;negative regulation of cell cycle;5.0;0.5089359064165209;0.5447089650691808;7.0970975870692286;42.34575940812408;3.5270983854209863;0.0014172744586806725;0.47061698731819834;[EHMT2, CHEK1, FBXO5, SFN, BARD1, PLK2, CDC6, ZWINT, EZH2, CDKN1A, PTPRK, BRCA2, DUSP1, PCNA, PTGS2, GPNMB, CDKN2C, LILRB1, SIPA1, GMNN, KNTC1, MSH6, MSH2, BLM, NACC2, GAS2L1, TGFB1, DHCR24, INHBA, NR4A1, BCL6, CNOT3, HHEX, TOPBP1, SMC1A, IFNG, RBBP8, CCL2, BUB1, E2F7, WEE1, RAD51]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[GRAP2, FCER1A, LAT2, BTK, PAK1, IGKC, IGLV1-44, LYN, IGKV3-20, LAT]
GO:0048812;neuron projection morphogenesis;7.0;0.6547035408479693;0.6782711356811852;8.502512989635898;62.99970935475633;4.360973225476049;0.002108543576046295;0.5739397388140403;[STMN1, SDC2, GP5, PTK2, NR4A2, LRFN4, OGN, NRP1, LRRK2, DCC, DNM2, SGK1, NLGN1, PAK1, SLITRK6, LINGO1, WEE1]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[AKT1, TNFSF11, F2R, NDFIP2, PLK2, TNFRSF10B, CCDC22, FASLG, NUP62, CD36, LTF, FLNA, CCL19, CARD9, CD4, LTBR]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[PYCARD, IL6R, MSH6, MELK, MSH2, LGALS12, BTK, LY96, TNFRSF11A, SFN, TGFB1, TNFSF12, CAV1, TNFRSF10C, TNFRSF10B, INHBA, CD28, CD24, CDKN1A, FASLG, BRCA2, CD3E, DCC, PAWR, TNFRSF1B, IFNG, TLR4, SORT1, G0S2, MLH1]
GO:0045666;positive regulation of neuron differentiation;8.0;0.6181399273706679;0.684069963685334;8.712233520617966;337.32148776029015;3.9481280100702625;0.011289846625707336;0.576907450041722;[SCARB2, CYFIP1, CPNE5, PLXND1, MEF2C, EPHA3, LYN, SYT2, CXCL12, BCL6, TCF4, EZH2, ROBO2, NRP1, NLGN1, PAK1, CNR1]
GO:0006144;purine nucleobase metabolic process;7.0;0.6954798709641801;0.6986593007392905;9.165900730544008;248.65741003558907;6.599019797332524;0.008322339736750976;0.6883935445785896;[DPYD, ACPP, PRTFDC1]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[CYFIP1, CD3G, IGHG1, FCGR3A, PAK1, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0097067;cellular response to thyroid hormone stimulus;6.0;0.8933024483968273;0.7697715367885581;9.485423408851448;110.48347060425422;7.004484905440688;0.003697782332456301;0.6813299963962409;[GHSR, KIT, GAS2L1, CTSS]
GO:0031338;regulation of vesicle fusion;6.0;0.7248374789738407;0.6855390520770648;8.935377071932177;48.20117096329211;5.514393750639154;0.0016132498139038735;0.6051266654433651;[CORO1A, EVI5, ANXA1, TBC1D9]
GO:0034605;cellular response to heat;5.0;0.8436909121759173;0.712086467948879;9.260799472366804;50.43140892920004;5.666199763507158;0.0016878938715389536;0.5800107312719123;[CDKN1A, PTGS2, LYN, CXCL10]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, HLA-DPA1, ANXA1, FCER2, HLA-DQB1, CCL13, LRRC19, PTAFR, PTGS2, ALOX5, CCL19, CCL18, IL12RB2, CCL23, CCL20, HLA-DPB1, PF4, CSF3R, F13A1, IL5RA, CXCL13, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, CXCL10, CXCL11, CXCL12, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, FASLG, TNFSF13B, TNFRSF1B, XCL1, CX3CR1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FCGR1B, IL2RB, TNFSF11, ACSL1, IL1R1, IL1R2, FLT3LG, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, PPBP, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR5, CCR2, IL17RB, CEACAM1, KIT, RHOU, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, IL18R1, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL6, CXCL9, CXCL1, CXCL3, CXCL2, CXCL5, GHR, LRRTM4, MMP9, IFNG, SAMHD1, NCAM1, CD4, LTBR]
GO:0043011;myeloid dendritic cell differentiation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;91.1712242271392;6.8867018697843045;0.003051418826107602;0.6753065664753021;[TGFB1, CAMK4, LTBR]
GO:0010635;regulation of mitochondrial fusion;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;36.654343885932605;7.57984905034425;0.0012267879030943493;0.738553198190834;[PID1]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[DOCK5, NRP1, NRP2, AKT1, CCR6, ANXA1, ANXA3, MMP9, IFNG, ADAM9, PFN1, HBEGF, PTGS2, TGFB1, PLK2, TEK]
GO:0022617;extracellular matrix disassembly;5.0;0.8653626801206646;0.7229223519212526;9.377209824211215;37.09213040667776;5.69953618377475;0.0012414402239614005;0.581715557354699;[MMP8, MMP9, CTSS, MMP12, CTSG, ELANE]
GO:0048821;erythrocyte development;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;33.53950096943652;6.832634648514029;0.0011225369138558525;0.639662265535933;[ARID4A, BCL6]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[CCNH, LGALS3, SNRPD2, SNRPD1, MAGOH, SNRPD3, SLBP, GTF2H1, SNRPG, SNRPE, SNRPF, SNRPA, LSM5, LSM3, ACIN1, RBMX]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[AKT1, BTK, TLR8, TLR7, TLR4, LY96, CARD9]
GO:1902902;negative regulation of autophagosome assembly;9.0;1.0;0.896240625180289;9.628524252492122;476.81513928252696;7.292166977892469;0.015958573606020727;0.769162383550154;[LRRK2]
GO:0043380;regulation of memory T cell differentiation;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;172.8848963572363;7.697632086000634;0.005786301894771495;0.7898978880348613;[BCL6]
GO:0001933;negative regulation of protein phosphorylation;9.0;0.6056485694559711;0.6990649099082746;8.75603614327636;664.693789818838;3.7392027077583316;0.02224670295966317;0.5874636255457587;[PID1, PPP2R1A, AKT1, ATF3, FLRT2, PRKAR2B, SFN, LYN, PKIG, CDKN1A, PTPRR, LRRC4, DUSP2, DUSP1, DUSP6, CEACAM1, TLR4, ENG, LRRC19, CDKN2C, NLRP12, PKN1, PYCARD, TSC2, FOXO1, TGFB1, CAV1, LRRK2, HHEX, LRRTM4, NUP62]
GO:0002903;negative regulation of B cell apoptotic process;10.0;0.8436909121759173;0.837086467948879;9.466005322994347;155.02018656046687;7.292166977892469;0.00518838613506862;0.7881627702307852;[BCL6]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CXCL6, CCL13, CXCL9, CSF3R, C5AR1, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, LGALS3, CCL8, CXCR1, CCL7, CCL5, CXCR2, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CXADR, CCL20, PPBP, CXCL10, CXCL11, XCL1, S100A8, PF4]
GO:0010524;positive regulation of calcium ion transport into cytosol;12.0;0.811012628672052;0.8536266269261705;9.4949928598676;446.85811756486936;5.825829909099042;0.01495593904869991;0.7460535250702665;[CXCL9, CD19, CAV1, TRPC1, F2R, CXCL10, P2RX5, CD4, CXCL11, XCL1, F2RL3]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[PAK1, TGFB1, AKT1, SLC8A1]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[LGALS3, SNRPD2, PPP2R1A, SNRPD1, MAGOH, SNRPD3, SNRPG, SNRPE, SNRPF, SNRPA, LSM5, LSM3, ACIN1, RBMX]
GO:0040036;regulation of fibroblast growth factor receptor signaling pathway;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;67.94038154209638;6.375876246018314;0.002273903427840277;0.6491829203200885;[RUNX2, DUSP6, SULF2]
GO:0032494;response to peptidoglycan;5.0;0.8653626801206646;0.7229223519212526;9.461470167828956;77.33766349313319;7.379178354882098;0.002588421997736798;0.6676125360964777;[C5AR1, CARD9, NLRP3, TREM2]
GO:0032495;response to muramyl dipeptide;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.66765988983927;7.004484905440688;0.0019970228791053504;0.6813299963962409;[JAG1, CARD9]
GO:0044871;negative regulation by host of viral glycoprotein metabolic process;8.0;1.0;0.875;9.628524252492122;465.7553848824157;9.083926447120524;0.015588413579381752;0.839552420951524;[PTX3]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RACGAP1, EZH2, DENND1B, NRP1, ARHGAP6, RHOG, CCL13, CCL19, CCL18, RANBP1, CCL23, CCL20, SIPA1, CXCL13, RGS1, F2R, TSC2, ACAP1, PRTN3, ADAP2, EVI5, LRRK2, TBC1D9, ARAP3, ALDH1A1, XCL1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:0009117;nucleotide metabolic process;7.0;0.4444416221570314;0.5731401763357162;7.314889323311491;170.44217484987414;3.7109655375767217;0.005704546204226714;0.5406983154264199;[ADCY9, FIGNL1, BST1, DTYMK, PTGS2, UNG, NT5E, MPP1, KMO, ATP1B1, PGD, MSH2, TGFB1, LRRK2, HK3, UPP1, DCK, ACPP, PRTFDC1, SAMHD1, RAN]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[CDA, ACPP, FBP1, HM13, SAMHD1, CD79A]
GO:0051044;positive regulation of membrane protein ectodomain proteolysis;9.0;1.0;0.896240625180289;9.628524252492122;964.0127980139503;7.069023426578259;0.03226464079433516;0.757750811958709;[IFNG, ADAM9, TNFRSF1B]
GO:0032488;Cdc42 protein signal transduction;9.0;1.0;0.896240625180289;9.628524252492122;29.60642063139588;7.697632086000634;9.9090025448413E-4;0.7898978880348613;[RHOU]
GO:0033211;adiponectin-activated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;55.92657384780918;8.16763571524637;0.0018718120960374526;0.7686126355688037;[ACSL1]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, PTGS2, SULF2, C3AR1]
GO:0035751;regulation of lysosomal lumen pH;11.0;0.8933024483968273;0.8790801765280758;9.523163736834295;144.4590765595299;7.292166977892469;0.004834915287719184;0.8053507106995271;[LRRK2]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, HHEX, BLNK, TPD52, CR2, IFNA14, IFNA16, NFAM1, MSH2, KIT, IFNA10, DLL1, CD79B, CD79A, IFNA21, BCL6, FCGR2B, ITM2A]
GO:0031394;positive regulation of prostaglandin biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.59462270081644;954.1434290848206;8.390779266560578;0.03193432189813256;0.8443458537639685;[ANXA1, AVPR1A, PTGS2]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, AGTR1, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, PPBP, MARCO, PNOC, GPR18, GPR19, GPR25, GABRB1, CD3E, CCR9, FFAR2, CCR6, CCR5, CCR2, GPR37, ANXA1, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, MC3R, CCL13, PTGER2, PTAFR, CXCR5, CXCR4, CXCR6, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, CCL19, GABRE, CCL18, GPR157, P2RY13, GABBR1, CCL23, SORT1, GABRA5, CCL20, P2RY14, GPR6, RAMP1, LGR4, F2RL3, PF4, CHRM2, CHRM1, CELSR1, CXCL13, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, ADRB2, GPR82, HRH4, DRD4, HTR1E, CAV1, GPR98, CXCL10, CXCL11, CXCL12, GNB2, TAS2R7, CXCL6, CXCL9, OR1G1, CXCL1, CXCL3, CXCL2, CXCL5, GRM5, PTGIR, GLP2R, XCL1, CX3CR1, LRP1, OR1E1, P2RY6, CCL8, CCL7, CNR1, P2RY2, OR2W1, CCL5, CCL4, CCL2, S1PR3, OR12D3, CCL1, S1PR5, TSHR, OR11A1]
GO:0006098;pentose-phosphate shunt;11.0;1.0;0.9324289523296623;9.628524252492122;549.7873240273956;7.212124270218933;0.018400886958728914;0.8012573229067359;[PGD]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, PPBP, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, CD68, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, TNFSF13B, PYCARD, IL6R, ICOSLG, CCR2, HLA-DPA1, HAVCR2, ANXA1, PDCD1LG2, XCL1, CD274, BLM, HHLA2, CORO1A, HLA-DMB, CCL5, CCL19, LILRB2, CD4, CD6, CD28, HLA-DPB1, CD24]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, EDNRB, AKT1, GHSR, LHCGR, POR, ADCY9, ABCB4, SLC30A10, FOXO1, PRKAR2B, LYN, EGR1, EGR2, TGFB1, CAV1, CDC6, NR4A2, NR4A1, CXCL12, HHEX, ANXA1, ARG1, GLP2R, TGFBR3, CEACAM1, TLR2, RETN, PTGS2, GNAI1, PAK1, SORT1, TSHR, TEK]
GO:0045736;negative regulation of cyclin-dependent protein serine/threonine kinase activity;12.0;0.8933024483968273;0.8947715367885583;9.585964638073326;2927.1185870500644;6.375876246018314;0.09796802487286638;0.7741829203200885;[CDKN1A, CDKN2C, HHEX]
GO:0097186;amelogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;26.73958370240551;7.474488534686424;8.949498024565515E-4;0.7053660038532718;[SLC24A4, CSF3R, ITGB4]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF13B, TNFSF13B, PYCARD, TNFSF11, TNFRSF1B, TNFRSF11A, TNFRSF17, TNFSF14, TNFSF12, TNFRSF10C, TNFRSF10B, LTBR]
GO:0051056;regulation of small GTPase mediated signal transduction;7.0;0.6799073451904818;0.6908730378524415;8.647694999480395;45.070113835906206;4.018171853803189;0.001508456149618737;0.5564088607247961;[STMN1, PDGFRB, F2R, TSC2, RASGRP4, RACGAP1, ABCA1, BCL6, GPR18, NRP1, ARHGEF10L, ARHGAP6, NUP62, PSD3, RALGPS2, PLEKHG1, RHOG, ARAP3, DNM2, RHOU, FBP1, FGD4, EPS8L1, SIPA1, F2RL3]
GO:0045860;positive regulation of protein kinase activity;10.0;0.6281612110245125;0.7293216173731766;9.003430535177193;1094.9224192180604;3.5309668621989068;0.03664606800502658;0.5958148214005239;[, CCNH, TCL1A, AKT1, PROK2, TNFSF11, ACSL1, SLC11A1, FPR1, TGFA, IQGAP3, PRKAR2B, PDGFC, ELANE, EGR1, ACE, FZD5, CDC6, AZU1, PTK2, NOX4, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, KIT, TLR4, CXCR4, PAK1, CCL19, PKN1, IL6R, PDGFRB, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, ADRB2, STAP1, DRD4, TGFB1, TNFRSF10B, GH1, CSPG4, LAT, LRRK2, GHR, GRM5, PSRC1, IFNG, CHI3L1, LTF, CCL5, EGF, CD4]
GO:0001878;response to yeast;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;28.654098265158677;8.390779266560578;9.59026881920657E-4;0.7522251544931926;[PTX3, ELANE]
GO:0001516;prostaglandin biosynthetic process;11.0;0.8933024483968273;0.8790801765280758;9.597752593825367;1037.183190875448;7.138016298065211;0.03471358799433119;0.7974674377644215;[MGST1, PTGS2]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, PDGFRB, GHSR, ANXA1, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CXCL13, CTGF, CXCL16, FGF5, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, FLT3LG, BTC, IFNA10, TGFA, ADRB2, PDGFC, IFNA21, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, PPBP, GH1, CXCL10, CXCL11, CXCL12, PNOC, OGN, CD320, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, PRL, CXCL3, IFNA8, CXCL2, CXCL5, TNFSF13B, IFNG, XCL1, HBEGF, CCL13, NLGN1, CLEC12B, RETN, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, EGF, CCL20, CMTM2, FCGR2B, PF4]
GO:0030177;positive regulation of Wnt signaling pathway;7.0;0.7307253602413294;0.7162820453778652;9.040737587590003;188.4547261984632;4.948759890378168;0.006307410087620234;0.6039991761920099;[LRRK2, HHEX, RUVBL1, NAIP, TLR2, JUP, EGF, CAV1, SULF2, LGR4]
GO:0044539;long-chain fatty acid import;11.0;1.0;0.9324289523296623;9.628524252492122;75.02792930111643;7.474488534686424;0.0025111172729558144;0.8146746435927894;[ACSL1, CD36, SLC27A2]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, VRK1, CORO1A, PTK2, ANXA1, RHOG, ARAP3, KIT, RHOU, CCL13, FGD4, CCL7, PDPN, CCL2]
GO:0045629;negative regulation of T-helper 2 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2589.4439345822343;8.390779266560578;0.08666635814222527;0.8916598066706847;[ANXA1, BCL6]
GO:0090630;activation of GTPase activity;7.0;1.0;0.8509193652572005;9.628524252492122;49.337455126924546;5.2552850506314295;0.0016512802222712962;0.6196748871422394;[CXCL13, EVI5, RHOG, TBC1D9]
GO:0043200;response to amino acid;5.0;0.6441938053840475;0.612337914552944;8.412128928167629;56.712201515420396;5.104244793218563;0.0018981063470534028;0.5512723279577749;[CTGF, ARG1, NAIP, PCNA, ABCB4, PDGFC, LYN]
GO:0046710;GDP metabolic process;10.0;0.8933024483968273;0.861892236059334;9.574457031221845;1314.1926939491284;7.138016298065211;0.04398484676983994;0.7802794972956796;[MPP1]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[EGF, BCL6]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[SKP2, ESCO2, SDC2, F5, NUCB1, IGFBP7, WFS1, CCDC22, UBE2M]
GO:0045986;negative regulation of smooth muscle contraction;8.0;0.7508913569872202;0.7504456784936101;8.98189708756707;66.40311154199819;7.138016298065211;0.002222452384390169;0.7400384854347593;[DOCK5, CALCRL, ADRB2, PTGS2]
GO:0045987;positive regulation of smooth muscle contraction;8.0;0.7671156992804218;0.7585578496402109;9.081980546124052;66.30038010178355;6.280566066213989;0.002219014055538479;0.6961884407023742;[GHSR, PTAFR, F2R, TACR3, PTGS2, KIT, PROK2]
GO:0043330;response to exogenous dsRNA;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;30.956451235720028;5.970411137910149;0.0010360845638621964;0.6284474158353811;[IFNA5, COLEC12, IFNA4, IFNA7, IFNA14, IFNA16, CAV1, IFNA2, CARD9, IFNA8, IFNA21, IFNA10]
GO:0034644;cellular response to UV;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;66.19362175939281;5.420364800990877;0.0022154409498949313;0.628117073252615;[CDKN1A, PTPRK, CHEK1, MME, PCNA, PTGS2, POLD1]
GO:0034769;basement membrane disassembly;6.0;1.0;0.8231203125901445;9.628524252492122;37.78527758723771;8.67846133901236;0.0012646392363027793;0.7669372290569613;[CTSS]
GO:0032227;negative regulation of synaptic transmission, dopaminergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.86833888550652;8.67846133901236;0.004547391028931578;0.8188169164668168;[PTGS2]
GO:0042129;regulation of T cell proliferation;8.0;0.6696747006330769;0.7098373503165385;8.89763674394933;80.78677358774456;4.7664383335842135;0.002703860608605884;0.6187558780415471;[TFRC, PYCARD, LGALS3, IL6R, ICOSLG, CD274, BLM, HHLA2, CORO1A, TGFB1, CD28, CD24, CD3E, TNFSF13B, CCR2, HLA-DPA1, HAVCR2, ANXA1, ARG1, PAWR, PDCD1LG2, XCL1, HLA-DMB, GPNMB, CCL5, CCL19, LILRB1, LILRB2, CD4, CD6, HLA-DPB1, CLC]
GO:1903077;negative regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;218.53196919702376;6.686031174322154;0.007314068343020746;0.7169239451870815;[TGFB1, PID1, AP2M1]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[CYFIP1, SLA2, STMN1, AKT1, BTC, BTK, EPHA3, SDC2, TGFA, SLC30A10, FLRT2, PDGFC, LYN, PTK2, NRP1, PTPRR, NRP2, CD3E, GAB1, KIT, HBEGF, PAK1, SORT1, SULF2, NCF4, CTGF, FGF5, GRAP2, AP2M1, PDGFRB, TSC2, KIF16B, BLK, RASGRP4, FOXO1, STAP1, TGFB1, CRIM1, BMX, GH1, CSPG4, GHR, BLNK, MMP9, REPS2, TRAT1, EGF, CD4, CD7, TEK]
GO:0045637;regulation of myeloid cell differentiation;6.0;0.620063164412167;0.633151894796228;8.465373442686442;67.16582126229967;4.39257856489138;0.002247979592334476;0.5477569846744829;[CSF3R, LGALS3, HOXA9, GPR171, TNFSF11, LHCGR, MEF2C, LYN, CCR1, NFE2, JAG1, INHBA, HMGB2, CEACAM1, IFNG, TLR4, LTF, DLL1, LILRB1, TMEM64, LILRB3, MEIS2, CD4, CAMK4, ACIN1, PF4]
GO:0046847;filopodium assembly;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;58.56724312331254;6.943860283624253;0.001960192920240494;0.6782296504172152;[FGD4]
GO:0019371;cyclooxygenase pathway;10.0;1.0;0.9152410118609203;9.628524252492122;253.27491700286936;7.379178354882098;0.008476883539459374;0.7926125360964777;[TBXAS1, PTGS2]
GO:0019372;lipoxygenase pathway;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;153.6575605806622;7.138016298065211;0.005142780269808322;0.7400384854347593;[ALOX5, PTGS2]
GO:0035723;interleukin-15-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.212124270218933;0.00101047745553359;0.7197477358342742;[CD4, IL2RB]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A1, SLC24A4, SLC8A1, SCN3A, SCN1A, SLC13A1, SLC6A16, SLC6A15, SLC12A1, ATP1B2, ATP1B1, SLC6A6]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[PDGFRB, GAS2L3, CXADR, TLN1, PFN1, CORO1A, RACGAP1, CORO2A, BCL6, NRP1, ARHGEF10L, CXCL1, ANXA1, RHOG, GAB1, KIT, RHOU, FGD4, PAK1, FLNA, KRT19, ZYX]
GO:0071902;positive regulation of protein serine/threonine kinase activity;11.0;0.6763753087927167;0.7706166067260205;9.206529842432747;1260.5827351979337;3.9422628906178643;0.04219056969626795;0.6340364598898325;[, CCNH, TCL1A, AKT1, PROK2, TNFSF11, ACSL1, FPR1, TGFA, IQGAP3, PDGFC, ELANE, FZD5, CDC6, NOX4, CD24, EZH2, MAP4K1, DUSP6, KIT, TLR4, CXCR4, PAK1, CCL19, PKN1, PDGFRB, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, ADRB2, DRD4, TGFB1, GH1, CSPG4, LRRK2, GHR, PSRC1, IFNG, LTF, EGF]
GO:0043068;positive regulation of programmed cell death;6.0;0.544374901031353;0.595307763105821;7.549082710812286;59.39447578849882;3.3868329606151195;0.001987879653083215;0.4963231076998412;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, CDKN1A, ANXA1, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, LRRK2, FASLG, NLRC4, CCL5, CCL2, P2RX1, PPP2R1A, SIK1, TNFSF12, ITM2C, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, PDGFRB, NLRP3, TGFB1, CAV1, INHBA, UBE2M, MMP9, DNM2, IFNG, CNR1, LTBR]
GO:0046697;decidualization;4.0;1.0;0.75;9.628524252492122;34.68251427445171;6.781341354126479;0.0011607925405295219;0.5967981122146513;[GHSR, PTGS2]
GO:0048754;branching morphogenesis of an epithelial tube;6.0;0.7436939687323844;0.6949672969563367;8.8813098506619;51.7127811195946;4.956792062075433;0.0017307802455913577;0.5766108891590862;[NRP1, PLXND1, HHEX, ENG, PAK1, TGFB1, EGF, PPP1CA]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[NRP1, ANXA1, PLK2, PTGS2]
GO:0002755;MyD88-dependent toll-like receptor signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.5544162803384;412.6549923027037;6.280566066213989;0.013811191226989502;0.7693087532925187;[LY96, CD36, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, CAV1, NR4A2, CXCL12, NOX4, CD24, KCND2, AGTRAP, TGFBR3, TLR2, CXCR4, PTGS2, PAK1, TEK]
GO:0002634;regulation of germinal center formation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;44.47967864407596;7.57984905034425;0.0014886948151053528;0.738553198190834;[MEF2C, BCL6, PKN1, TNFSF13B]
GO:0002636;positive regulation of germinal center formation;8.0;1.0;0.875;9.628524252492122;213.8757386662325;8.67846133901236;0.007158228497490581;0.8188169164668168;[TNFSF13B]
GO:0051926;negative regulation of calcium ion transport;8.0;0.7140352122741334;0.7320176061370667;8.890925309361343;69.46225493434336;5.666199763507158;0.0023248391606816524;0.6647697194109919;[PTGS2, DRD4, TGFB1, LILRB1, LILRB2, GEM]
GO:0050712;negative regulation of interleukin-1 alpha secretion;11.0;1.0;0.9324289523296623;9.628524252492122;999.3037873052855;9.777073627680469;0.033445798446087804;0.9324289523296623;[IL1R2]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1, HMGB2, KLRK1, NLRP3, CD36, CAMP, HAVCR2, DEFA4, CARD9, RNASE6, RNASE3, DEFA1, LYZ, TLR2]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TCL1A, AKT1, IFNA14, IFNA16, IFNG, IFNA10, PTGS2, PAK1, IFNA21, TGFB1, CAV1]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, CDH5, GHSR, IL1R2, TNFRSF1B, CALCRL, NT5E, NLRP3, ELANE, NLRP12, TEK, FCGR2B]
GO:0061844;antimicrobial humoral immune response mediated by antimicrobial peptide;6.0;1.0;0.8231203125901445;9.628524252492122;44.28377145688295;5.682729065458369;0.0014821379778550245;0.6137353412716126;[CXCL6, CCL13, CXCL9, HIST1H2BK, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, PPBP, CXCL10, CXCL11, LTF, PF4]
GO:0046597;negative regulation of viral entry into host cell;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.95196338807416;6.832634648514029;0.002843265762795464;0.7244212536750128;[GSN, IFNA2, PTX3]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CCR1, CXCR1, CCL5, CXCR2, CXCR4, CCR6, CCL19, CCR5, CCR2]
GO:2000521;negative regulation of immunological synapse formation;8.0;1.0;0.875;9.628524252492122;159.58048984171964;9.083926447120524;0.005341015381885652;0.839552420951524;[LGALS3, HAVCR2]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[EDNRB, C3AR1, TNFSF11, IL1R1, IL1R2, BTK, AGTR1, PLA2G7, CD19, ELANE, LYN, BST1, CD28, FFAR2, CCR2, ANXA1, IL17RB, TLR10, TLR7, TLR4, TLR2, PTGS2, NT5E, IGKC, CCL18, CCL23, NLRP12, ZYX, CDH5, IGHG1, GHSR, S100A8, SUCNR1, CALCRL, C5AR1, TNFRSF11A, IGLV1-44, NLRP3, SELE, BCL6, IGKV3-20, TNFAIP6, CR2, CR1, TNFRSF1B, XCL1, CNR1, CCL5, CCL4, CD6, TEK, FCGR2B]
GO:0035666;TRIF-dependent toll-like receptor signaling pathway;13.0;0.9326813400603323;0.9288956347978027;9.592156608321247;413.3481394832653;6.599019797332524;0.013834390239330937;0.8000291440890255;[LY96, TLR4]
GO:0055072;iron ion homeostasis;9.0;0.811012628672052;0.801746939516315;9.292052015870908;38.23288616879122;5.395046993006588;0.0012796202927058053;0.6721435792979885;[STEAP4, TFRC, SLC40A1, HEPH, SLC11A1, LTF, CYBRD1, LCN2]
GO:0060420;regulation of heart growth;6.0;0.7586651285174919;0.7024528768488905;9.260799472366804;65.94608890727007;5.75172193694532;0.0022071562480994867;0.6172636399279519;[MEF2C, DUSP6, TGFBR3, PAK1, BASP1]
GO:0031065;positive regulation of histone deacetylation;10.0;0.8933024483968273;0.861892236059334;9.571365838652174;1219.9035963218012;6.8867018697843045;0.04082907552693193;0.7674272657460779;[TGFB1, LRRK2, BCL6]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, CD33, HAVCR2, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, TLR2, PTGS2, PAK1, GPNMB, PDPN, CCL23, CDKN2C, LILRB1, LILRB2, PKN1, SIRPG, CDH5, DACH1, F2R, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, RARRES3, CAV1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, PTGIR, TGFBR3, IFNG, XCL1, DLL1, CCL8, CCL2, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, AGTR1, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, HLA-DMB, EPCAM, FLNA, CCL19, IL12RB2, LRG1, HLA-DPB1, CHRM1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, CXCL10, CXCL12, BCL6, FASLG, TNFSF13B, XCL1, CX3CR1, SMARCD3, CCL5, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, FLT3LG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, CD320, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, AVPR1A, CEACAM6, KIT, GNAI2, PAK1, CXCR2, LILRB2, SIRPG, IL6R, PDGFRB, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, CXCL5, GLP2R, MMP9, TGFBR3, IFNG, LTF, DLL1, S1PR3, EGF, MEIS2, TSHR, CD4, CD6, TEK]
GO:0046598;positive regulation of viral entry into host cell;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;85.02443603688559;7.57984905034425;0.0028456913571300335;0.7626338329336335;[CD4]
GO:0090394;negative regulation of excitatory postsynaptic potential;8.0;0.8933024483968273;0.8216512241984136;9.551563211355994;398.5774323400213;7.57984905034425;0.013340027964019948;0.7626338329336335;[LRRK2]
GO:0090271;positive regulation of fibroblast growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;76.08155514529764;8.67846133901236;0.002546381181758862;0.7669372290569613;[PTGS2]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, IL6R, PDGFRB, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, GNAI2, PAK1, CCL5, ELANE]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, CCL4, TRAT1, P2RX5, CD4]
GO:0070584;mitochondrion morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;64.70445744698846;6.781341354126479;0.002165599960519628;0.6370391240755715;[PID1, SSBP1]
GO:0071310;cellular response to organic substance;4.0;0.44223782556504454;0.47111891278252227;5.954033535830285;41.65973036582596;2.624021992742989;0.0013943136840210083;0.3841926067383783;[CYFIP1, PID1, TFRC, SPINT2, MYB, AKT1, MEF2C, ADCY9, SPINT1, PADI2, ABCB4, FPR2, SLC30A10, IQGAP3, KLRK1, PRKAR2B, PDGFC, ST3GAL6, LYN, ABCA1, JUP, CDC6, NOX4, EZH2, GABRB1, HLA-DPA1, HAVCR2, ANXA1, DUSP1, ARG1, CCL13, PTAFR, PTGS2, CCL19, CCL18, P2RY13, CCL23, GSN, CCL20, NR1H2, ZYX, PF4, CXCL13, SLC8A1, PYCARD, CDH1, TLE4, LHCGR, DGAT2, CD180, ADAM9, CD274, BLM, CALCRL, CORO1A, FOXO1, IGFBP7, OSBPL7, DEFA4, DEFA1, CXCL10, CXCL11, SLC26A3, MCM7, LRRK2, TREM2, TNFRSF1B, XCL1, MCM2, CX3CR1, LRP1, CEBPE, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, RAD51, KLF5, FCGR2B, AQP9, TCL1A, EDNRB, TNFSF11, PTGDR, RUNX2, POR, KCNQ1, BTK, SIK1, EPHA3, STXBP2, EGR1, EGR2, EGR3, PPBP, ROBO2, NRP1, CTSS, FFAR2, CTSG, CD36, CCR5, MAP4K1, MME, PDCD1LG2, AVPR1A, CEACAM1, KIT, TLR4, TLR2, DTYMK, PTGER2, CXCR4, GNAI1, PAK1, CD58, LILRB1, LILRB2, NLRP12, CD68, RAMP1, IL18R1, PDGFRB, GHSR, KMO, KIF16B, CSF2RB, ADRB2, STAP1, NLRP3, GAS2L1, TGFB1, CAV1, INHBA, NR4A2, NR4A1, ALPL, CXCL6, CXCL9, HMGB2, CXCL1, CXCL3, CXCL2, CXCL5, GHR, TMEM100, GRM5, GLP2R, DNM2, CHI3L1, COLEC12, TSHR, CD4, RBMX]
GO:0070585;protein localization to mitochondrion;6.0;0.7586651285174919;0.7024528768488905;8.935377071932177;32.77360880529348;5.514393750639154;0.001096903192380182;0.6051266654433651;[LRRK2, AKT1]
GO:0019064;fusion of virus membrane with host plasma membrane;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;56.73089801191601;7.8311634786251565;0.0018987321019653565;0.7514054297404357;[CD4, CXCR4, CCR5]
GO:0070346;positive regulation of fat cell proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;8.390779266560578;0.0021335122412550348;0.7522251544931926;[PID1]
GO:0071677;positive regulation of mononuclear cell migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;295.2864367703214;6.686031174322154;0.009882971298162901;0.7381645703673706;[CCR1, TGFB1, FPR2, PLA2G7, LGALS3, CXCL10, CXCL12, CCL5, CCL1, CCR2]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[DENND5B, ATP2A3, FASLG, SLC8A1, CCR5, TRPC7, TRPC1, F2R, CACNA2D3, TMEM37, XCL1, SLC24A1, SLC24A4, CCL19]
GO:0032147;activation of protein kinase activity;11.0;0.6799073451904818;0.7723826249249031;9.164951513576677;1096.8683293671154;4.034070439870987;0.03671119586651001;0.6387315022281249;[, AKT1, PROK2, TNFSF11, MAP2K2, SLC11A1, F2R, ADAM9, C5AR1, FPR1, TGFA, ADRB2, IQGAP3, PRKAR2B, PDGFC, DRD4, TNFRSF10B, CSPG4, LRRK2, GHR, MAP4K1, DUSP6, KIT, CHI3L1, TLR4, CXCR4, PAK1, CCL19, EGF, PKN1]
GO:0034201;response to oleic acid;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;46.1874048850311;7.9853141584524145;0.0015458508755362855;0.7314896500084853;[DGAT2, ACSL1]
GO:0071318;cellular response to ATP;7.0;1.0;0.8509193652572005;9.628524252492122;523.2473722673394;7.212124270218933;0.01751261865772571;0.7197477358342742;[PTGS2]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[DENND1B, CD3G, CD3E, GRAP2, ICOSLG, HLA-DPA1, BTK, HLA-DQB1, HHLA2, PAK1, HLA-DQA1, HLA-DRB4, TRAT1, BMX, CD4, CD28, HLA-DPB1, HLA-DRA, LAT]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, IFNA2, TREM2, CD3E, GHR, GRM5, CD36, IL6R, IFNG, BANK1, KIT, HBEGF, TGFA, CCL5, STAP1, LYN, TGFB1, ACE, EGF, GH1, CD4, CSPG4, CD24]
GO:2000773;negative regulation of cellular senescence;7.0;1.0;0.8509193652572005;9.628524252492122;164.4250159730019;7.004484905440688;0.005503157311709213;0.7091290490632969;[BCL6, PLK2, SLC30A10]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD274, HHLA2, CD3E, TNFSF13B, PAK1, KLRK1, GRAP2, BTLA, AKT1, CCL19, ICOS, ICOSLG, LYN, TNFSF14, CAV1, PDCD1LG2, CD28, CD24]
GO:0031296;B cell costimulation;9.0;1.0;0.896240625180289;9.628524252492122;298.24063740046915;8.67846133901236;0.009981845734645991;0.8400575416471059;[CD320, TNFSF13B]
GO:0048305;immunoglobulin secretion;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;133.331941423656;8.390779266560578;0.004462500088492957;0.8253454670833372;[TNFSF13B]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[CDKN1A, EHMT2, LRRK2, LAMP2, UPP1, SIK1, ATF3, SEH1L, FOXO1, GAS2L1]
GO:0001782;B cell homeostasis;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;22.00128503895464;6.599019797332524;7.363632103827933E-4;0.6883935445785896;[LYN, MEF2C, TNFRSF13B, TNFSF13B, PKN1]
GO:1903955;positive regulation of protein targeting to mitochondrion;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;662.5702871444865;6.311337724880743;0.022175631236180954;0.7380031166185408;[FZD5, RHOU]
GO:0090280;positive regulation of calcium ion import;9.0;0.8653626801206646;0.8289219652406215;9.420884887713877;92.69484377077161;6.8867018697843045;0.0031024130010644134;0.7484268790654467;[PDGFRB, LGALS3, CXCL12, CCL2]
GO:0050860;negative regulation of T cell receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;309.61561130321576;6.8867018697843045;0.010362555874359037;0.7271862538851576;[LGALS3, CEACAM1, PVRIG, PAWR, UBASH3A]
GO:0002503;peptide antigen assembly with MHC class II protein complex;7.0;1.0;0.8509193652572005;9.628524252492122;45.61567929762514;8.67846133901236;0.0015267157346454312;0.7947362817240173;[HLA-DMA, HLA-DMB, HLA-DRA]
GO:0048312;intracellular distribution of mitochondria;6.0;1.0;0.8231203125901445;9.628524252492122;33.240769060787855;7.57984905034425;0.0011125386257146447;0.710754145523778;[LRRK2]
GO:0015939;pantothenate metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;165.9330644697462;8.16763571524637;0.005553630337739711;0.7686126355688037;[VNN1, VNN2, VNN3]
GO:2000300;regulation of synaptic vesicle exocytosis;10.0;0.7307253602413294;0.7806036919815851;9.310070521373587;261.41947140868626;6.558197802812269;0.00874947444579898;0.7506275524841266;[NLGN1, LRRK2]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[CXCL13, PYCARD, EDNRB, GHSR, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, KLRK1, STAP1, NLRP3, ELANE, ABCA1, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, PPBP, SELE, CXCL10, CXCL11, ALPL, CXCL6, CXCL9, HMGB2, CXCL1, TREM2, FASLG, CXCL3, CXCL2, CXCL5, CTSG, CD36, CCR5, HAVCR2, PTGIR, ARG1, PDCD1LG2, TNFRSF1B, TLR4, CX3CR1, CEBPE, PTGER2, PTGS2, CNR1, CCL2, IL12RB2, CCL20, NR1H2, LILRB1, LILRB2, CD6, LTBR, PF4]
GO:0032497;detection of lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;150.00497270670016;8.390779266560578;0.005020531440782482;0.7522251544931926;[LY96, TREM2, TLR4]
GO:2000660;negative regulation of interleukin-1-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;306.2706419112467;8.16763571524637;0.010250602759086841;0.7926932703116032;[IL1R2]
GO:0016601;Rac protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;6.7325511899570465;9.9090025448413E-4;0.719302980950052;[CYFIP1, RHOG, RHOU]
GO:0032092;positive regulation of protein binding;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;32.707776742429765;5.311165509025885;0.0010946998524811438;0.5618542629869587;[NRP1, PLXND1, LRRK2, MEF2C, MMP9, LRP1, PLK2, CAV1, RAN]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, PDGFRB, MAP2K2, VRK1, MELK, BTK, SIK1, BLK, LYN, BMX, PTK2, LRRK2, MAP4K1, KIT, PAK1, CAMK4, TEK]
GO:0042178;xenobiotic catabolic process;4.0;0.5846489169746516;0.5423244584873258;7.369741782156469;50.9456663911434;7.379178354882098;0.0017051056059885297;0.6273715242355574;[ACSL1]
GO:0045444;fat cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[STEAP4, FFAR2, RETN, ADRB2, PTGS2, FOXO1, EGR2, LAMB3, NR4A2, NR4A1, LRG1]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[LRRK2, STMN1, AKT1, AES, SLPI, ADRB2, CCL23, CAV1, PPP1CA]
GO:0023014;signal transduction by protein phosphorylation;8.0;0.7248374789738407;0.7374187394869203;9.153100555777048;203.92357026499027;3.9689311377000256;0.006825138377471068;0.5779713229561524;[, IL5RA, FGF5, TNFSF11, KCNH1, PDGFRB, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, LYN, TGFB1, PTK2, LAT, LRRK2, CCR5, SPTAN1, MAP4K1, DUSP6, KIT, HBEGF, PAK1, CCL5, CCL2, NCAM1, EGF, IL2RB, TEK]
GO:0000023;maltose metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;66.17358362000121;8.67846133901236;0.002214770291402649;0.7669372290569613;[MGAM]
GO:0002438;acute inflammatory response to antigenic stimulus;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;43.66651068845287;7.57984905034425;0.0014614788154342952;0.710754145523778;[CD6, CXCR2, ELANE]
GO:0006914;autophagy;4.0;0.6729672293956388;0.5864836146978194;8.39638057119949;37.75222312160081;4.39717627414001;0.001263532933085;0.4748717991491287;[LAMP2, HGS, S100A8, FOXO1, ITGB4, LRRK2]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, TNFRSF1B, MMP9, POR, NAIP, NLRC4, PTGS2, SFN, TNFSF14, TNFRSF10C, TNFRSF10B, DHCR24]
GO:0016973;poly(A)+ mRNA export from nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;122.0533615230405;7.004484905440688;0.004085016169282269;0.7734506956670166;[HHEX]
GO:0034260;negative regulation of GTPase activity;6.0;1.0;0.8231203125901445;9.628524252492122;61.14468506277762;5.970411137910149;0.0020464575824072424;0.6284474158353811;[LRRK2, KLRK1]
GO:0071727;cellular response to triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;168.80270344913424;8.67846133901236;0.005649674571872418;0.8188169164668168;[TLR1, TLR2]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[CXCL6, C5AR1, CXCL1, PPBP, CXCL3, CXCL2, CXCL5, CXCR2, C3AR1, XCL1, CCL19, PF4]
GO:0034142;toll-like receptor 4 signaling pathway;12.0;0.8436909121759173;0.8699657686781033;9.485423408851448;412.6549923027037;6.943860283624253;0.013811191226989502;0.8032296504172152;[ITGAM, LY96, TLR4]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, EGF, CAV1, SULF2, LGR4, NAIP]
GO:0090022;regulation of neutrophil chemotaxis;10.0;0.8933024483968273;0.861892236059334;9.517298617381897;138.915002380433;6.193554689224359;0.004649360114287637;0.731979686697602;[MPP1, CXCL6, C5AR1, CXCL1, PPBP, CXCL3, CXCL2, CXCL5, BST1, CXCR2, C3AR1, XCL1, CCL19, JAM3, PF4]
GO:0090140;regulation of mitochondrial fission;7.0;0.8653626801206646;0.7836007053175329;9.34084218004034;36.654343885932605;6.641579411751319;0.0012267879030943493;0.6905700452391912;[LRRK2]
GO:0002573;myeloid leukocyte differentiation;5.0;0.7369933605727446;0.6587376921472925;8.741221057491218;45.128183839147766;5.311165509025885;0.0015103997003676221;0.5618542629869587;[TFRC, TREM2, HHEX, TNFSF11, MEF2C, MMP9, OSCAR, KIT, PRTN3, CEBPE, TNFRSF11A, CCL19, TGFB1, CAMK4, LTBR]
GO:0034137;positive regulation of toll-like receptor 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;505.2767808384828;8.16763571524637;0.01691115913508416;0.8139338954918922;[TLR1]
GO:0034130;toll-like receptor 1 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR1]
GO:0033160;positive regulation of protein import into nucleus, translocation;10.0;1.0;0.9152410118609203;9.628524252492122;970.0189350156829;7.292166977892469;0.03246566079461078;0.7881627702307852;[IFNG, LRRK2]
GO:0009051;pentose-phosphate shunt, oxidative branch;11.0;1.0;0.9324289523296623;9.628524252492122;369.5748319676681;8.67846133901236;0.012369337030203025;0.8762458687964789;[PGD]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CXCL10, CD4, ALPL]
GO:0022028;tangential migration from the subventricular zone to the olfactory bulb;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;22.93064785239865;8.390779266560578;7.67468147376534E-4;0.7800242071602487;[LRRK2]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[GJC1, TMEM100, HHEX, TGFB1, CAV1, TIE1, PTK2, TGFBR3, ENG]
GO:0022027;interkinetic nuclear migration;6.0;1.0;0.8231203125901445;9.628524252492122;68.32040627354414;7.9853141584524145;0.0022866225136017795;0.7314896500084853;[HHEX]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, FASLG, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, IFNG, FBP1, MEIS2]
GO:0045591;positive regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;997.8066164740876;7.292166977892469;0.03339568948573388;0.7881627702307852;[TGFB1, BCL6, IFNG, LILRB2]
GO:0035338;long-chain fatty-acyl-CoA biosynthetic process;8.0;1.0;0.875;9.628524252492122;500.3176215265477;6.8867018697843045;0.016745180535867314;0.7271862538851576;[ACSL1, TECR, ELOVL6]
GO:0070542;response to fatty acid;5.0;0.6696747006330769;0.6250783621774587;8.578702127993445;43.78950961223322;5.382624473008031;0.0014655954787213788;0.5655086777281872;[PID1, CTGF, AKT1, FFAR2, CD36, PTGDR, DGAT2, ACSL1, TGFBR3, TLR2, PTGER2, PTAFR, PTGS2, P2RY6, CCL19]
GO:0051900;regulation of mitochondrial depolarization;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;53.421926806676176;6.781341354126479;0.0017879838136067236;0.6977174774718518;[LRRK2]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPRK, DUSP2, DUSP1, DUSP6, TPTE, PTPRE]
GO:0034128;negative regulation of MyD88-independent toll-like receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;7.8311634786251565;0.011871713162238609;0.7967266896635242;[LY96, TLR4]
GO:0071636;positive regulation of transforming growth factor beta production;6.0;0.7980440201809971;0.722142322680643;9.34084218004034;65.64212018022187;6.943860283624253;0.0021969826883592772;0.6782296504172152;[MYB, XCL1, PTGS2]
GO:0033030;negative regulation of neutrophil apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;301.33162323320204;9.083926447120524;0.010085298248760914;0.8607930461318132;[CXCR2]
GO:0050829;defense response to Gram-negative bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.407625775213448;0.0023911797157970473;0.627465598881932;[IGHM, HIST1H2BK, HMGB2, PYCARD, CTSG, IL6R, CAMP, DEFA4, SLC11A1, RNASE6, RNASE3, AZU1, DEFA1, LYZ, CD4, BPI, TLR4, LTF]
GO:0090362;positive regulation of platelet-derived growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;63.8503607109938;9.083926447120524;0.0021370141114030452;0.7876727335416686;[PTGS2]
GO:0044267;cellular protein metabolic process;5.0;0.3358520568840654;0.45816704030295297;5.574370570853267;80.86766357206795;1.6585685600933726;0.0027065679235849286;0.3750602851554211;[, SLA2, AKT1, DUSP2, DUSP1, DUSP6, IL12RB2, PKN1, KCNH1, BLK, PKMYT1, BMX, HM13, IL2RB, TNFSF11, SNRPD3, BTC, BTK, NAIP, SDC2, EGR2, PTK2, MUC15, SPTAN1, KIT, PCNA, UBE2M, GHR, TEK, ST3GAL6, IGHA1, BARD1, PLK2, ASGR1, ASGR2, CIT, GSN, NUCB1, IL5RA, FGF5, LAMP2, MAP2K2, VRK1, NRBP1, CCDC22, LAT, TPTE, NLRC4, PPIL4, PPP2R1A, ESCO2, POR, SIK1, PRL, TLR7, TLR4, TLR2, QPCT, NLRP3, CBX4, LTF, HIST1H2BK, BUB1, WEE1, EHMT2, KRTCAP2, MEF2C, PADI2, PADI4, IQGAP3, LYN, ABCA1, LYZ, EZH2, F5, F13A1, RUVBL1, AP2M1, S100A8, FOXO1, PTPRE, ST6GALNAC2, LRRK2, CCL8, CCL5, CCL2, TIE1, CCNH, EPHA3, PTPRR, FKBP14, PTPRK, BRCA2, CTSG, CCR5, PAK1, PPP1CA, GXYLT2, PDGFRB, CCNE1, KLHL14, PSEN2, RASGRP4, GALNT6, EGF, CDK14, ANXA1, HBEGF, FAM105A, GTF2H1, CHRM1, ABHD12, GRAP2, MACROD2, STK32B, MELK, NACC2, IGFBP7, WFS1, MARCH3, MARCH1, RNF24, CHEK1, SKP2, BCL11A, MAP4K1, B3GNT5, SGK1, CAMK4, ARID4A, CSF2RB, ADRB2, TGFB1, TGFBR3, NCAM1]
GO:1902823;negative regulation of late endosome to lysosome transport;7.0;1.0;0.8509193652572005;9.628524252492122;62.897271694127355;9.083926447120524;0.0021051150797329523;0.8154717862087246;[LRRK2]
GO:1901727;positive regulation of histone deacetylase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1450.469379047906;7.9853141584524145;0.04854590477904197;0.8407982897480031;[LRRK2]
GO:0006906;vesicle fusion;6.0;0.6799073451904818;0.6630739851853854;8.563813515499694;63.097974703971886;5.192106149009898;0.0021118324288514666;0.5886448625081389;[DYSF, STX11, SYT2]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[CCL13, CCL23, ANXA1, CCL20, TNFRSF11A, LGALS3, CCL8, CCL7, CCL5, CCL4, TNFSF11, CCL2, XCL1, CCL1, CCL19, CCL18, IL6R, CCR2]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[CTGF, PYCARD, TNFSF11, MAP4K1, TNFRSF11A, PAK1, CCL19, FZD5, CARD9, PKN1, LTBR, FCGR2B]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, ANXA1, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, FASLG, NLRC4, CCL5, CCL2, P2RX1, PPP2R1A, SIK1, TNFSF12, ITM2C, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, PDGFRB, NLRP3, TGFB1, CAV1, INHBA, UBE2M, MMP9, DNM2, IFNG, CNR1, LTBR]
GO:0033148;positive regulation of intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;233.77170011230152;7.379178354882098;0.007824128421887714;0.7523715242355574;[, PAK1, SKP2]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[IL18RAP, MYB, AKT1, BTK, MGST1, FOXO1, NR4A2, NOX4, EZH2, LRRK2, PTPRK, CD36, ANXA1, ARG1, MMP9, DNM2, PCNA]
GO:0034356;NAD biosynthesis via nicotinamide riboside salvage pathway;12.0;1.0;0.9481203125901445;9.628524252492122;2003.6404315682985;7.069023426578259;0.06706004208527355;0.8096304993685645;[PTGS2]
GO:0036413;histone H3-R26 citrullination;11.0;1.0;0.9324289523296623;9.628524252492122;343.59953251902647;9.083926447120524;0.011499967133908778;0.8969813732811862;[PADI2, PADI4]
